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Atherosclerosis is the leading cause of death in the developed world. The accumulation of low-
density lipoprotein cholesterol (LDL-C) in the arterial wall leads to the formation of foam cell 
lesions. The growth of lesions is influenced by a number of genetic and lifestyle factors. Over-
time, lesions encroach the vessel lumen, impeding blood flow and increasing risk of 
cardiovascular events including myocardial infarction and stroke. Statins have been effective 
at reducing risk for cardiovascular events, however, even when target LDL-C levels are met 
there remains a significant residual risk. Clearly, a detailed investigation into the mechanism 
of foam cell lesion growth is required to explore new drug targets to ease the burden on the 
health care system.  
 
Calcium/calmodulin-dependent protein kinase II (CaMKII) is a nodal signalling protein in 
endothelial cell (EC) and vascular smooth muscle cell (VSMC) physiology. In vascular disease, 
CaMKII has been shown to promote endothelial dysfunction and vascular smooth muscle cell 
proliferation. Both of these pathologies are involved in the early stages of atherosclerosis so 
it is intriguing to speculate that CaMKII also contributes to atherosclerosis. We have previously 
shown systemic inhibition of CaMKII in an atherosclerotic model (ApoE-/- mice) reduces foam 
cell lesion development. However, there are multiple isoforms of CaMKII (D, E, G and J) and 
associated splice variants. These sub-types are differentially expressed in the tissues of the 
body and have shown contrasting roles. A global inhibition of CaMKII is not a feasible target 
due to the important physiological functions of these multiple isoforms. Therefore, it is crucial 
we identify the isoform(s) contributing to foam cell lesion growth so a more specific 
therapeutic target can be explored.  
 
Firstly, the predominant isoforms of CaMKII were identified in the major cell types of the 
vasculature. The aortic tree was dissected from ApoE-/- mice at 13- (early atherosclerosis) and 
20-weeks (mid-atherosclerosis). In addition, human umbilical vein endothelial cells (HUVECs), 
human coronary artery endothelial cells (HCAECs) and human coronary artery smooth muscle 
cells (HCASMCs) were cultured. PCR and Western blotting was run for CaMKIIG and J isoforms. 
Results showed CaMKIIG as the predominant isoform in human and mouse vascular cells. In 
addition, at the mRNA level, splice variants G2, G3 and G6 were detected. CaMKIIG expression 
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was high at 13-weeks in the ApoE-/- mouse and levels persisted at 20-weeks, suggesting the G 
isoform is the most likely isoform contributing to atherosclerosis.  
 
To investigate if CaMKIIG signalling contributed to foam cell lesion development, we next 
employed a genetic approach. ApoE-/--mice were crossed with CaMKIIG-/- to generate a novel 
ApoE-/-CaMKII-/- (dKO) mouse model. At 20-weeks there was extensive atherosclerosis in the 
aortic sinus of female, but not male groups. Histological analysis showed there was a strikingly 
significant reduction in foam cell lesion content in female ApoE-/-CaMKIIG-/-, compared to 
ApoE-/-CaMKIIG+/+ litter mate controls. This indicates the CaMKIIG isoform is a critical player in 
the early development of atherosclerosis. 
 
To further test the mechanistic role of CaMKIIG in foam cell lesion development, an opposite 
strategy was performed whereby an AAV-mediated overexpression approach was utilised. 
ApoE-/-CaMKIIG-/- mice were put on a high-fat diet at 12-weeks to accelerate atherogenesis. At 
16-weeks of age, the left carotid arteries of ApoE-/-CaMKIIG-/- mice were ligated to increase 
shear stress and further promote foam cell lesion growth in a localised area. AAV-particles 
harbouring the CaMKIIG2 or control (scrambled) gene sequence were then introduced to the 
ligated left carotid artery. Ligation of the carotid artery led to a range of variation in foam cell 
lesion progression. Histological analysis of the carotid artery revealed the foam cell lesion area 
and stenosis from CaMKIIG2-mCherry mice showed a trend towards an increase, despite low 
n numbers due to adverse complications in 20% of the ligated mice. 
 
In summary, a number of genetic and molecular biological techniques have been used to 
provide evidence to show CaMKIIG contributes to the early stages of atherosclerosis. 
Importantly, there is still work that needs to be done to further validate this mechanism and 
the potential contribution of other delta variants and/or other isoforms. This novel study has 
provided foundation evidence of CaMKIIG as a specific target for treatment. The results 
provide impetus to continue the investigation of CaMKIIG that ultimately, could lead to a 
pharmacological intervention to treat the early progression of atherosclerosis. 
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Chapter 1: Introduction 
 
Cardiovascular disease (CVD) is the most significant health problem and burden on the health 
care system in the developed world. Atherosclerosis or coronary artery disease (CAD) is the 
major CVD characterised by ‘fatty’ arteries. Atherosclerosis manifests into a range of 
pathologies as well as life threatening events including myocardial infarction (MI) and stroke. 
In 2017, CVD was estimated to be responsible for 17.8 million deaths globally [1]. Clearly there 
is a major burden on the health care system that, in turn, provides strong impetus for research 
into the pathogenesis of atherosclerosis.  
 
 
1.1 The cardiovascular system 
 
The cardiovascular system (CVS) is composed of the heart and a number of specialised vessels 
which supply the tissues and vital organs around the body [2]. Oxygenated blood is ejected 
out of the heart at high pressure (~120mmHg) into the systemic circulation and travels to 
organs by a pressure gradient through a diverging network of arteries [3]. The arterial network 
diverges further at the target organ into a fine network of vessels, termed capillaries, which 
are specialised for gas exchange and diffusion of nutrients [4]. As well as providing nutrients 
to the organ at the capillary bed, the systemic circulation is just as vital for the removal of CO2 
and other byproducts of cellular metabolism. Following gas exchange at the capillary bed, de-
oxygenated blood rich in CO2 is collected via venules and converges into a lower pressure 
network of vessels called veins and returned to the heart [2]. At the heart, blood is pumped 











Figure 1.1: Basic schematic of the cardiovascular system (CVS). The CVS is made up of the heart and 
blood vessels including arteries and veins. Oxygenated blood (red) is ejected out of the heart into the 
systemic circulation and is conducted to the organs around the body via arteries. At the organ the artery 
diverges into a fine network of blood vessels termed capillaries (purple). Deoxygenated blood (blue) is 
drained via venules and collected into the systemic veins to be returned to the heart. At the heart 
deoxygenated blood is pumped into the pulmonary circulation to offload CO2 and pick up O2. Figure 
adapted from https://basicmedicalkey.com/the-circulatory-system-2/. 
  
 3 
1.1.1 Structure of the Vessel Wall 
 
The blood vessels, which compose the CVS supplying the organs around the body have three 
main layers. Both arteries and veins have the same layers, however the composition and size 
of each specific layer varies allowing different functions. The arteries are specifically adapted 
to provide an efficient delivery network in a high-pressure environment.  
 
The three layers of an artery include the tunica intima, media and adventitia (Figure 1.2) [5]. 
The tunica intima is the inside layer of the artery exposed to the vessel lumen. This layer 
consists of a single layer of endothelial cells (ECs) on an extracellular matrix rich in elastic fibres 
called the internal elastic lamina (IEL). The endothelium plays a key role in both restricting and 
facilitating the entry of substances between the blood and sub-intimal space [6]. The ECs also 
release a number of substances that have anti-adhesive and antithrombotic properties to 
allow laminar flow of blood [7].  
 
The middle layer of the artery wall is the tunica media. In an artery, this region, occupied by 
vascular smooth muscle cells (VSMCs), makes up the bulk of the total vessel size [8]. VSMCs 
have a critical role in the generation of vascular tone to maintain physiological blood pressure 
(BP) through constriction and relaxation [9]. Modulation of tone is critical in regulating blood 
flow in response to a change in metabolic demand. This is regulated mainly by extrinsic 
mechanisms such as the autonomic nervous system and locally released growth factors and 
vasoactive substances [10]. 
 
The outer most layer of the artery wall is the tunica adventitia which is separated from the 
tunica media by a tight bundle of elastin fibres, termed the external elastic lamina (EEL). This 
layer is composed of tightly bound collagen and elastin, important for providing structural 
support [8]. Additionally, in the larger arteries, the adventitia contains a network of micro 








Figure 1.2: Structure of an artery. The artery wall is composed of three distinct layers. The tunica intima 
consists of a single layer of endothelial cells which sits on a matrix of elastin fibres called the internal 
elastic lamina. The tunica media is the largest layer of the vessel wall and contains smooth muscle cells. 




The maintenance of a healthy artery is critical to provide efficient transport of blood around 
the organs of the body. The arteries are exposed to a volatile high pressure environment. The 
ECs and VSMCs are equipped with a number of inherent defense mechanisms through the 
release of active substances which promote vascular health. Over time, cumulative insult to 
the vascular wall reduces proper functioning of the cells of the vasculature and promotes the 





1.2 Pathogenesis of Atherosclerosis 
 
Atherosclerosis is a vascular pathology characterised by the formation of lipid-laden lesions 
(atheroma) on the inner layer of the artery wall (Figure 1.3). Atherosclerosis is multifactorial, 
meaning the disease progression is a cumulative effect from a number of genetic and 
environmental risk factors [13]. The most significant risk factor for the development of 
atherosclerosis is elevated plasma low-density lipoprotein cholesterol (LDL-C) [14-16]. Other 
risk factors include hypertension, type II diabetes, smoking and physical inactivity [17-19]. 
 
The two main hypotheses describing how atherosclerosis is initiated include the LDL-C and the 
response to injury (endothelial dysfunction) hypothesis [20, 21]. In the LDL-C hypothesis, the 
atherosclerotic lesion starts as a small streak of LDL-C in the artery wall [22]. LDL-C becomes 
oxidised and promotes an inflammatory response leading to the recruitment of monocytes to 
the vascular wall. Monocytes differentiate into macrophages and carry out phagocytosis of 
LDL-C/ox-LDL-C. In the process of lipid accumulation, macrophages transform into foam cells. 
Additionally, inflammatory signaling molecules promote migration and proliferation of VSMCs 
from the media to the sub-intima driving lesion growth. Over-time the atherosclerotic lesion 
can undergo further compositional changes that make the lesion vulnerable to rupture. 
Thrombolysis of atherosclerotic lesions are responsible for ischaemic attack including 
myocardial infarction (MI) and stroke [23]. For the purpose of this thesis, the early 




1.2.1 Endothelial Dysfunction – the initiation of atheroma 
 
The endothelial cells (ECs) that line the lumen of the artery wall play a critical role in vascular 
health. In a healthy artery, endothelial cells regulate the entry and exit of substances between 
the blood and vessel wall. These include hormones, nutrients and cells of the immune system. 
ECs release vasoactive substances such as nitric oxide (NO), prostacyclin and bradykinin for 
dilation and endothelin and angiotensin II for constriction [24] [25] [26] [27] [28] [29]. 
Additionally, NO has added protective functions to promote a non-adhesive surface for 
laminar blood flow [30, 31]. Over time, cumulative damage to the endothelial wall leads to a 
loss of function of these defense mechanisms and ECs become unable to maintain vascular 
homeostasis [32]. Endothelial dysfunction is a primary event in vascular disease such as 
atherosclerosis [20, 33].  
 
Atherosclerosis is predisposed in curved and bifurcating sites around the aortic tree [26]. 
These regions are exposed to turbulent oscillatory patterns of shear stress which promote 
endothelial dysfunction [34, 35]. In mammalian arteries, these regions include the aortic arch, 
brachiocephalic artery, coronary arteries and the carotid artery bifurcation [36]. Endothelial 
dysfunction is associated with a change in appearance of the endothelial cell structure from a 
thin elongated to a contracted appearance [37]. This is associated with increased permeability 
properties promoting the deposit of circulating atherogenic substances such as LDL-C into the 
vessel wall [22, 38]. Alongside increased permeability properties, the endothelial cells express 
adhesion molecules such as vascular cell adhesion molecule 1 (VCAM-1) and intracellular cell 
adhesion molecule 1 (ICAM-1) [39, 40]. These adhesion molecules allow ligation of circulating 
immune cells such as monocytes to the vessel wall. Collectively, increased adhesion and 







Figure 1.3: The pathogenesis of atherosclerosis. Endothelial dysfunction leads to the expression of cell 
adhesion molecules including VCAM-1. Circulating LDL cholesterol becomes deposited in the artery wall 
leading to an inflammatory response. Over time, LDL cholesterol becomes oxidised and promotes the 
recruitment and infiltration of monocytes into the sub-intima. Monocyte-derived macrophages engulf 
the oxidised LDL-C and differentiate into foam cells. Foam cells release cytokines, chemokines, growth 
factors and reactive oxygen species (ROS) which promote a switch in VSMC phenotype from contractile 
to synthetic. In the synthetic phenotype, VSMCs migrate to the sub-intima space and proliferate driving 
atherosclerotic lesion growth. Worthington, 2016. 
  
 8 
1.2.2 The Inflammatory response – monocytes to macrophage-foam cells 
 
Atherosclerosis is a chronic inflammatory disease that involves a complex environment of 
signalling molecules including chemokines, growth factors and reactive oxygen species (ROS). 
These signalling molecules culminate to drive an inflammatory response to ameliorate insult 
to the vessel wall. However, with sustained insult to the vascular wall the immune response 
loses the ability to maintain vascular health and atherosclerotic lesions present throughout 
the arterial tree. There are two main populations of monocytes that are important in the 
initiation and progression of atherosclerosis. These include resident macrophages and 
circulating monocytes [41, 42].  
 
In the healthy artery there is a small population of macrophages that reside in the vascular 
wall [41]. Over time, LDL-C within the artery wall becomes oxidised triggering a local 
inflammatory response [43]. This is mediated, in-part, through the activation of toll-like 
receptors (TLRs) on macrophages and other cell groups of the vasculature [44, 45]. The 
activation of TLRs leads to pro-inflammatory signalling through the expression of cytokines 
like TNF-D and transcription factors such as nuclear factor kappa B (NF-NB) [46]. NF-NB is a 
transcription factor critical for regulating the expression of a large number of genes involved 
in the inflammatory response. In resident macrophages, activation of TLRs promotes 
phagocytic activity for LDL-C clearance [47]. Additionally, macrophages release TNF-D and IL-
1E, which diffuse into the local environment and have effects such as promoting adhesion 
molecule expression in ECs [40, 48]. Collectively, this early inflammatory response functions 
to stimulate phagocytic activity of resident macrophages but also promote the recruitment of 
circulating monocytes. 
 
Circulating monocytes in the blood are recruited to the endothelial wall through an increased 
expression of the adhesion molecules, VCAM-1 and ICAM-1. Monocytes express a variety of 
integrins on the cell surface including lymphocyte function-associated antigen-1 (LFA-1), 
macrophage-1-antigen (Mac-1) and very late antigen 4 (VLA-4). LFA-1 and Mac-1 interact with 
ICAM-1 whereas VLA-4 primarily interacts with VCAM-1 [49-51]. Once the monocyte is bound 
to the endothelial wall via a specific integrin, migration of the monocyte into the sub-intima 
space can occur. This migration can be either transcellular, requiring transport through both 
the apical and basolateral membrane, or paracellular, between cells [52].   
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As monocytes migrate into the sub-intima, they are exposed to a new environment of 
cytokines and growth factors which stimulate differentiation into macrophages. Some of these 
signalling molecules include interferon J (IFN-J), ox-LDL-C, TNF-D, IL-10 and macrophage 
colony stimulating factor (M-CSF) [53]. As differentiation occurs, macrophages increase 
expression of a range of scavenger receptors which have the ability to take up LDL-C and ox-
LDL-C [54, 55]. Additionally, macrophages carry out pinocytosis, or the incorporation of the 
extracellular environment by endocytosis including cytokines and LDL-C [56, 57]. In the 
process of LDL-C uptake, macrophages transform into foam cells [58, 59]. Foam cells also 
contain ATP binding cassette transporters, ABCA1 and ABCG1, that are important for 
cholesterol efflux [60, 61]. The balance between lipid transport into and out of foam cells is 
critical to prevent the cytotoxic effects of excess LDL-C uptake [62, 63]. When lipid 
accumulation overtakes storage capabilities, lipid pooling occurs in the extracellular matrix 
(ECM). Histologically, this is observed as the lipid core [64]. 
 
With disease progression, excessive foam cell lipid accumulation leads to endoplasmic 
reticulum (ER) stress and the activation of apoptotic cell pathways [65, 66]. This triggers 
efferocytosis (phagocytosis) of the apoptotic cell by neighbouring macrophages to clear 
cellular debris [67]. With lesion progression, the increase in lipid pooling and apoptotic cell 
bodies becomes too much for phagocytic activity and secondary necrosis occurs [68]. This is 




1.2.3 Vascular smooth muscle cells – driver of lesion size 
 
The vascular smooth muscle cells (VSMCs) are another major cell group critical to the 
development of atherosclerosis. VSMCs can display two distinct structural and functional ends 
of diversity as well as a number of intermediates [10]. In a healthy artery, VSMCs display a 
contractile phenotype important for the maintenance of arterial tone. In contrast, in 
development or disease, VSMCs switch to a synthetic phenotype characterised by increased 
migration and proliferation [10]. 
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In the contractile phenotype, VSMCs have a long spindle-like structure. Additionally, 
contractile VSMCs maintain a high expression of ion channels and molecular machinery which 
facilitate VSMC contraction [70, 71]. In response to certain stimuli or environmental cues, the 
phenotypic state of VSMCs is modulated to a synthetic state. In the synthetic state, VSMC 
loses the contractile filaments and has an increase in the factory organelles including 
endoplasmic reticulum (ER) and Golgi apparatus [72]. Functionally, VSMC have increased 
proliferation and migration as well as the ability to synthesise ECM.  
 
Macrophage-foam cells in the sub-intima release cytokines, like TNF-D, which activates the 
NF-NB transcription factor to promote the expression of a specific subset of cytokines such as 
interleukin-6 (IL-6) [73]. IL-6 diffuses into the local vessel wall environment and acts in a 
paracrine manner to stimulate production of platelet-derived growth factor (PDGF) in VSMCs 
[74]. PDGF is a potent mitogen that activates a range of signalling pathways including mitogen-
activated protein kinase (MAPK). Activation of MAPK stimulates a series of phosphorylation 
events that trigger the VSMCs into the cell cycle [75]. Alongside proliferation, the MAPK 
pathway promotes cytoskeletal rearrangements to drive migration [76]. VSMCs also produce 
matrix degrading enzymes such as matrix metalloproteinase 9 (MMP-9), which facilitate 
migration from the tunica media to the intima [77, 78]. Collectively, proliferation and 
migration of the VSMCs to the tunica intima is a major mechanism for lesion growth [79]. 
 
The dynamic modulation of VSMC phenotype is further highlighted when VSMCs migrate to 
the sub-intima. At the tunica intima VSMC can carry out phagocytic activity similar to 
neighbouring macrophages and foam cells [80]. This is achieved through expression of 
cholesterol transporters [81, 82]. As the lesion develops VSMCs are responsible for the 
synthesis and secretion of the ECM. This includes a number of glycoproteins which can 
influence stability of developing lesion. For example, IFN- J released by macrophages leads to 
the production of collagen to promote the development of the fibrous cap over the growing 
lesion [83].  
 
In summary, VSMCs display a range of synthetic phenotype functions that all promote 
atherosclerosis. These include proliferation, migration, lipid accumulation and ECM synthesis. 
Ultimately, VSMCs are the major cell group responsible for growth of the lesion as well as the 
composition.  
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1.2.4 Classification of Atherosclerotic Lesions 
 
Atherosclerotic lesion growth is dynamic and progresses over decades. There is an extensive 
classification system that details the different lesion phenotypes throughout disease 
progression [69, 84]. However, for simplicity, this extensive system can be more broken down 
into four main lesion categories. Each lesion type is categorised based on lesion size and the 
physical composition of lesion components. The four types include; fatty streak, intermediate 
lesion, fibrous plaque and advanced plaque (Figure 1.4). 
 
The fatty streak is the first clinical indication of atherosclerosis indicated by expansion of the 
tunica intima alongside the accumulation of fat droplets in the sub-intima space. These early 
lesions have been identified in children and teenagers from post-mortem examination [85]. 
The intermediate lesion contains lipid droplets and foam cells derived from monocytes and 
VSMCs. The intermediate lesion progresses to the fibrous lesion at the appearance of a fibrous 
cap over the developed lipid core [84, 86]. At this point, other cells of the immune system are 
recruited to the lesion [87, 88]. An advanced plaque is characterised by a necrotic lipid core 
[69]. Other components include calcification, infiltration of blood vessels and thinning of the 
fibrous cap. These components all culminate to influence the stability of a lesion and 









Figure 1.4: Classification of atherosclerotic lesions. Intimal thickening and lipid droplet accumulation 
(1). Intermediate lesion consists of foam cells in a growing sub-intima (2). Lipid core, presence of 
immune cells and developed fibrous cap (3). Necrotic core, capillary infiltration and calcification and 
thinning of the fibrous cap (4). Original Figure, Luke Worthington, 2020. 
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1.3 Atherosclerosis – a clinical perspective 
 
Atherosclerotic lesions remain stable and asymptomatic for decades [91, 92]. The progression 
of lesion development is influenced by a number of genetic and environmental factors 
including elevated LDL-C, hypertension, type II diabetes and smoking [14, 16, 18, 19, 93, 94]. 
Controlling the progression of atherosclerotic lesion growth is not the only issue. With disease 
development, morphology of the lesion also changes toward a phenotype that is susceptible 
to rupture [95]. The rapid thromboembolic complications that arise from lesion rupture 
including myocardial infarction (MI) and stroke are life-threatening and present a challenge to 
the clinic. 
 
The progressive build-up of atherosclerosis in the coronary arteries leads to a reduction in 
blood flow exerting metabolic stress on the heart, termed angina [96]. Angina is an early 
clinical symptom of CAD, and patients commonly described experiencing shortness of breath 
and tightness across the chest [97].  However, angina is not always the first clinical symptom 
of CAD and in fact death can be the first symptom with no previous warnings [98, 99]. The 
asymptomatic nature of lesion growth prior to any clinical symptoms means the disease is 
poorly monitored in its early stages [92]. Instead, patients will receive treatment only after 
they have come into the clinic with angina, or after a major adverse cardiac event (MACE) 
including myocardial infarction and stroke [100, 101]. Therefore, clinical treatment for 
atherosclerosis only occurs at a very late stage in its progression. 
 
 
1.3.1 Pharmacological treatment of CAD 
 
The benefits of improving lifestyle factors such as increasing exercise for decreased 
cardiovascular risk has been exhausted in the literature [86, 102, 103], and both lifestyle and 
pharmacological intervention to improve cardiovascular outlook is promoted and used in the 
clinic [104-106]. CAD is multifactorial and many patients have pre-existing co-morbidities such 
as type II diabetes and hypertension which need to be considered for drug selection [15, 107, 
108]. Therefore, in reality, there is not a blanket subset of drugs for treatment of CAD in every 
patient. Instead, a range of drug classes including anticoagulants, antiplatelet therapy, 
nitrates, Ca2+ channel blockers, statins and beta-blockers are used to treat CAD and improve 
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vessel health [109-113]. This results in a cocktail of pharmaceuticals needing to be tailored to 
the needs of each patient [114, 115].  
 
For the acute management of unstable angina, relief is best achieved with dual anti-platelet 
therapy, commonly clopidogrel and aspirin [116, 117]. This provides an effective mechanism 
to prevent blood clots while reducing blood viscosity and vessel wall shear stress [118-120]. 
For relief against angina which persists for extended periods, additional drugs are also 
effective at ameliorating symptoms. Ca2+ channel blockers and nitrates are used to promote 
relaxation and inhibit contraction of VSMCs to increase vessel diameter and improve blood 
flow [24, 121, 122]. Beta-blockers are also sometimes used in patients with CAD to decrease 
the metabolic demands of the heart and also increase the diastole phase of the cardiac cycle, 
when blood is circulating through the coronary arteries [109, 123]. In summary, the action of 
these drugs aim to improve CAD by augmenting coronary blood flow, while limiting myocardial 
oxygen demands. 
 
The gold standard drug therapy for the treatment of coronary artery disease is the use of 
statins [124, 125]. Statins inhibit 3-hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase, 
an essential enzyme in the production of LDL-cholesterol [126]. LDL-cholesterol is the major 
promoter of atherosclerotic lesions and strongest risk factor for cardiovascular disease related 
morbidity and mortality [14-16]. The use of statins and the resulting reduction in serum LDL 
lipid profile has been shown to be beneficial in reducing risk for CAD and MACE [113, 124, 125, 
127]. The implementation of lifestyle modifications and pharmacological approaches to treat 
CAD has been successful in improving prognosis [109-112]. However, these approaches are 
not sufficient for patients with severe CAD, or after a MACE and will require surgical 
intervention to restore adequate blood flow [128]. 
 
 
1.3.2 Tools for evaluating Atherosclerosis  
 
Upon arrival in the clinic, doctors will evaluate the magnitude and extent of CAD in each 
patient to decide what surgical intervention is required to re-vascularise diseased vessel 
segment. The coronary artery angiogram was pioneered by Mason Sones in the early 1960s 
[129]. Today, it remains the gold standard method for the evaluation of coronary artery 
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disease [105]. In this technique, a catheter is inserted into the radial or femoral artery and 
guided to the aortic root where a contrast dye is released. By normal haemodynamics, the dye 
flows through the left and right main coronary arteries and subsequent diverging branches 
around the heart. An X-ray is then taken to capture the coronary arteries and any degree of 




Figure 1.5: Coronary angiogram to detect narrowing of the left circumflex artery. Contrast dye is 
released into the coronary network and an X-ray photo captured in the right anterior oblique (RAO) 
plane. The LCx artery in (A) is shows no signs of narrowing compared with the LCx artery in (B) which 
highlights a significant stenosis present (red ring). Images adapted from https:// 
www.heartfoundation.org.nz/shop/heart - healthcare / angiography - and -angioplasty-2018.pdf.  
 
 
While the coronary artery angiogram provides an excellent tool for the evaluation of stenosis, 
it is limited to this. Lesion progression is associated with increased calcification [130] which 
stems from both trans-differentiation of vascular smooth muscle cells to an osteogenic 
phenotype and vesicle mediated mineralisation due to apoptosis of macrophages and VSMCs 
within the necrotic core [131, 132]. The effect this plays on lesion stability is still a topic of 
debate [133]. While studies have shown contradictory findings, it is very likely the impact of 
calcification on lesion stability is additionally influenced by the geometric location of the artery 
as well as lesion type [26, 34]. Regardless of this, epidemiological evidence has shown 
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increased levels of calcium in the coronary arteries is a strong marker for coronary artery 
disease and associated MACE [134, 135].  
 
The use of cardiac computed tomography (CT) scan technology can provide structural data on 
vascular calcification (Figure 1.6) [136, 137]. One of the advantages of this method is 
visualisation of arteries in 3D without the need of any X-ray dyes. Clinicians have developed 
complex scoring systems that rank magnitude and severity of CAD within patients for risk of 
MACE [138]. This is based on a number of variables including genetics, extent of 
atherosclerosis, presence of calcification, and the location within the coronary network. Taken 
together, the coronary angiogram and cardiac CT scan provide a good prognostic tool for the 






Figure 1.6: Comparing coronary CT scan with traditional coronary artery angiogram. Coronary artery 
CT scan showing a segment of extensive calcification (white) in the RCA, marked by the red arrow (A). 




1.3.3 Surgical intervention to treat CAD 
 
The two most common forms of heart revascularisation by surgical intervention are coronary 
artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) (stenting). CABG 
has become one of the most commonly performed surgeries since its introduction in 1968 
[140]. The procedure involves the removal of a donor vessel from another part of the body, 
which is then grafted from the aorta to the coronary artery, distal to the diseased segment 
(Figure 1.7). This restores blood flow through the ischaemic tissue and alleviates stress on the 
heart muscle. The extent of grafts required reflects the magnitude of CAD and there are 
several commonly used graft donors, including the radial artery, saphenous vein and internal 
mammary arteries (IMA). The IMA are useful as only one side needs to be grafted as it 
originates off the subclavian close to the aortic arch. Figure 1.7B-C shows a single vs triple 




Figure 1.7: Common coronary artery bypass graft surgical approaches. The three main coronary 
arteries which supply the heart are the right coronary artery (RCA), left anterior descending coronary 
artery (LAD) and left circumflex artery (A). The extent of surgical intervention, whether it is a single or 
triple CABG (B-C,) reflects amount and location of atherosclerosis (yellow stars). 1: Left internal 
mammary artery is grafted onto the LAD distal to the diseased segment. 2: The saphenous vein (blue) 
removed from the leg is grafted from the aorta to the right coronary artery. 3: The radial artery has 
been removed from the hand and grafted from the aorta to the LCx.   
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The other common procedure for restoring blood flow through diseased arteries is PCI [141]. 
A balloon tip catheter is inserted via the femoral or radial artery and guided to the narrowed 
artery. The catheter is positioned adjacent to site of atherosclerosis and the balloon is inflated 
to expand the stent. The balloon is deflated, catheter removed and blood flow is restored to 
the ischaemic region (Figure 1.8) [142]. One of the main issues with PCI is restenosis 
(recurrence of stenosis). The physical force of the stent against the atherosclerotic vessel wall 
can cause physical damage which stimulates a local inflammatory response [143]. This leads 
to VSMC proliferation and migration toward the intima, a common step in the 
pathophysiology of atherosclerosis. Importantly, restenosis puts patients at risk of MACE, so 
revascularisation by CABG is the next option [144]. In more recent times, the development of 
drug-eluting stents (DES) has reduced restenosis and ultimately the need for repeat surgery 




Figure 1.8: Percutaneous coronary intervention (PCI). The stent is navigated through the arterial 
network to the site of stenosis (A). The stent is expanded using a balloon tip catheter and fixed in place 




The ‘SYNTAX Trial’ is a prospective study started in 2005 evaluating the effectiveness of CABG 
vs PCI with DES, where 1800 patients were randomly assigned to either CABG or PCI group 
[146]. Over the 10-year period following up, there has been no significant differences in deaths 
between CABG, 212 (24%) and PCI, 248 (28%) [147]. Interestingly, there were differences for 
CABG vs PCI groups with respect to the severity of coronary artery disease. In patients with 
three-vessel disease, there were significantly fewer deaths in CABG compared to PCI group. 
However, no differences were seen in patient deaths with left main CAD between CABG and 
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PCI group. Collectively these results suggest both CABG and PCI are effective at preventing 
MACE, however CABG is more protective for patients with severe CAD.  
 
The majority of interventions discussed are for the treatment of atherosclerosis in the context 
of the coronary arteries. However, the coronary arteries are not the only region prone to 
extensive atherosclerosis. The carotid artery also has a high burden of atherosclerosis (Figure 
1.9) [148, 149], where the build-up of plaque in the carotid artery is associated with increased 
risk of stroke and other ischaemic brain injuries [150]. There are two main interventions to 
treat atherosclerosis in the carotid arteries; carotid angioplasty with stent, previously 
described, and carotid endarterectomy [151, 152]. To carry out the carotid endarterectomy, 
the carotid artery is cut open and the lesion surgically scraped away from the vessel wall to 
restore blood flow. While the surgical procedure is invasive and requires ongoing 
pharmaceutical management, for patients with extensive carotid atherosclerosis, it remains 




Figure 1.9: Atherosclerotic disease in the carotid artery. The left and right common carotid artery 
branch from the aortic arch and brachiocephalic artery, respectively. Each common carotid artery 
further bifurcates into the internal and external carotid artery (A). Frozen segment of the common 
carotid artery from a 79-year old male (B). Cross section of the carotid artery shows extensive 
atherosclerosis occupying majority of vessel with characteristic necrotic core. The vessel lumen has 




In conclusion, there are a number of methods to diagnose the extent and severity of 
atherosclerosis. Alongside pharmacological intervention to ameliorate symptoms of CAD, 
arteries prone to atherosclerotic disease can be re-vasculated by surgical intervention. The 
introduction of these surgical approaches has had a significant impact at reducing the number 
of MACE. However, the lesions responsible for ischaemic events are of an advanced 
phenotype late in disease progression. This highlights the importance of researching the 
cellular mechanisms which promote early foam cell lesion development. The ability to target 
atherosclerosis in an earlier stage of its progression would have a positive impact on all the 
clinical manifestations that arise from atherosclerotic disease. Without screening of early 
lesions and the ability to treat them at an earlier stage these surgical interventions will remain 




1.4 Research tools in atherosclerosis – ApoE-/- mouse model 
 
In the research world there are a number of excellent tools for studying the pathogenesis of 
atherosclerosis. In vitro studies have been a useful model at providing insight into the cellular 
mechanisms that contribute to atherosclerosis. However, the environment that promote 
lesion growth is difficult to establish in an artificial setting. Atherosclerosis is a chronic 
inflammatory disease involving an interplay of autocrine and paracrine signalling between 
cells of the immune system and vascular wall. For this reason, the research field has adopted 
a number of animal models which has exponentially increased our knowledge of the 
mechanisms and therapeutic targets around lesion growth.  
 
The first use of animals for atherosclerosis research was in 1908, when Ignatowski showed 
that rabbits fed a diet high in protein and fat displayed atherosclerotic lesions within the vessel 
wall of the aorta [153]. Since then, a variety of animal models have contributed to our 
understanding of the pathophysiology of atherosclerosis, however the mouse has become the 
gold standard model [154]. Like Ignatowski, other groups utilised the major risk factor for 
atherosclerosis by putting mice on a high fat diet (HFD) to induce hyperlipidaemia and lesion 
development [155-157].  
 
One of the main issues with wild-type mice on the HFD is their inherent resistance to 
atherosclerosis [158]. This stems from the fact mice have a cholesterol metabolism that allows 
efficient clearance of LDL-C [159]. It was not until the evolution of the molecular biology field 
and discovery of gene editing techniques where the mouse emerged as the gold standard 
model for atherosclerosis research. Scientists targeted proteins involved in reverse 
cholesterol transport, the removal of cholesterol from peripheral tissues via biliary excretion 
[160]. The most successful genetic manipulations to induce hyperlipidaemia in mice is the 
knockout of the ApoE or the LDL receptor (LDLR) gene [160]. Targeted deletion of these genes 
interrupts the uptake of chylomicrons and LDL-C by the liver resulting in the net accumulation 
of LDL-C in the blood [161, 162]. The resulting hyperlipidaemia in both models drives the 
development of atherosclerotic lesions throughout the arterial tree that are characteristic 
with the human disease [162, 163]. The main advantage of the ApoE-/- model is the 
development of lesions on a normal chow diet (ND) at a faster rate relative to LDLR-/- mice 
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[164, 165]. In our own lab and others around the world, the ApoE-/- mouse model has been 
consistently used to unravel some of the mechanisms driving atherosclerotic lesion growth. 
 
The wild-type mouse has plasma cholesterol of 75-110 mg/dl on a ND [162]. By knocking out 
the ApoE gene these cholesterol levels are elevated to an average of 600 mg/dl on a ND [162]. 
Additionally, supplementation of ApoE-/- mouse with the HFD augments plasma cholesterol 
levels to >1000 mg/dl [162, 166]. One of the major differences between mice and humans is 
a differential lipoprotein expression [167]. Mice transport the majority of cholesterol bound 
to HDL and have only small concentrations of LDL-C and VLDL-C [168]. Furthermore, the high 
levels of the anti-atherogenic lipoprotein HDL is thought to provide the inherent protection 
from atherosclerosis in the wild-type strain [158]. In contrast, humans transport the majority 
of cholesterol on the atherogenic LDL and VLDL particles [169]. Even with these differences in 
lipid profile between species, ApoE-/- mice rapidly develop atherosclerotic lesions with a 
physiology and anatomy comparable to humans [84, 170]. 
 
In humans, atherosclerosis is present in the coronary and carotid arteries whereas the ApoE-
/- mouse lesions are primarily located in the aortic arch, aortic sinus and brachiocephalic artery 
(Figure 1.10) [171, 172]. This is likely to reflect differences in shear stress across the vessel 
wall between species. At 6 weeks, ApoE-/- mice exhibit monocyte adherence to the endothelial 
cell wall as well as sub-intimal deposits of LDL-C [162]. This progresses to pockets of foam cell 
lesion growth throughout the aortic tree at 15-weeks, visible to the naked eye. At 20-weeks, 
extensive lesions are present containing macrophages, foam cells, VSMC, ECM and a distinct 
fibrous cap [162]. Even as the lesion progresses to an advanced phenotype the disease 
remains comparable between humans and mice. This advanced stage of the lesion is 
characterised by pockets of calcification and a growing necrotic core with infiltrating blood 










Figure 1.10: Atherosclerosis in the ApoE-/- mouse. Dissection of a 20 week female ApoE-/- mouse 
highlights atherosclerosis indicated by the opaque vessel wall. Extensive atherosclerosis is present in 
the brachiocephalic artery, carotid arteries, left subclavian artery and the lesser curvature of the aortic 
arch (A). A 4µm section of the aortic arch vessel wall was treated with Verhoeff van Gieson stain. 
Features of the vessel wall include VSMCs (brown), internal elastic lamina (black), extracellular matrix 
(pink) and foam cells (grey). At 20-weeks expansion of the intima (white double arrow) and foam cell 




A limitation of this model is that at a very advanced stage of atherosclerosis, there is no 
spontaneous lesion rupture and thrombo-embolic complications which manifest at the 
advanced stage of the human disease [173]. However, for us, and other labs around the world 
who are interested in unravelling the cellular mechanisms that drive atherosclerotic lesion 









1.5 Calcium calmodulin-dependent protein kinase II (CaMKII) 
 
The development of foam cell lesions is an early event in the pathogenesis of atherosclerosis 
driven by a combination of ECs, VSMCs and macrophages [13]. More specifically, when the 
pathology is broken down to the specific functional changes occurring in each cell type, it 
includes endothelial dysfunction, macrophage lipid accumulation and a synthetic VSMC 
function [13, 20, 22, 79]. A number of signalling pathways have been identified, which 
promote these cellular changes to drive foam cell lesion growth [75, 174]. However, many of 
these pathways are incomplete and lack important detail about intermediate signalling 
proteins that will be involved. These intermediate signalling proteins could provide novel drug 
targets. 
 
Calcium calmodulin-dependent protein kinase II (CaMKII) is a nodal signalling protein in 
cellular physiology [175, 176]. CaMKII translates upstream Ca2+ signals to downstream cellular 
response by phosphorylation of target proteins [177, 178]. These responses include acute 
cellular changes in activity and gene transcription events. CaMKII activity has been strongly 




1.5.1 CaMKII Structure and Function 
 
CaMKII is a holoenzyme composed of 10-12 subunits [183]. There are four separate genes that 
encode the D, E, G and J isoforms [184, 185]. Each subunit contains a catalytic, regulatory and 
a C-terminal association domain, which orchestrates multimerisation of the holoenzyme. The 
catalytic domain is at the N-terminal and carries out serine/threonine kinase activity (the 
addition of a phosphate group to molecule). The regulatory domain links the two terminal 
ends and contains a binding pocket for the catalytic region. In the inactive state the catalytic 
domain is folded over in a ‘hinge-like’ fashion and bound to the regulatory pocket [186]. 
 
Increases in the intracellular Ca2+ concentration leads to the formation of a Ca2+-calmodulin 
complex. Ca2+-calmodulin bind a specific region in the regulatory domain inducing a 
conformational change [187]. The conformational change relieves the interaction between 
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the catalytic and regulatory domain, allowing serine/threonine kinase activity (Figure 1.11). 
Therefore, while Ca2+ levels are elevated, CaMKII can carry out target phosphorylation of 
proteins [178]. Importantly, when Ca2+ is removed from the intracellular environment, 
calmodulin dissociates and the enzyme is inactive. This mechanism of auto-inhibition in the 











Figure 1.11: Structure and function of CaMKII monomers. CaMKII monomers are composed of a 
catalytic, regulatory and association domain. In physiological conditions the catalytic domain is bound 
to the regulatory domain and the enzyme is inactive. Increases in Ca
2+
 stimulates binding of calmodulin 
to the regulatory domain relieving the interaction with the catalytic domain. In this active state CaMKII 
carries out phosphorylation of target substrates. When Ca
2+ 
is extruded out of the environment, CaM 




1.5.2 Chronic activation of CaMKII 
 
Even though CaMKII activity is tightly regulated by auto-inhibition, prolonged activation of the 
holoenzyme leads to inter-subunit auto-phosphorylation of adjacent subunits (Figure 1.12). 
More specifically, a phosphate group is added to threonine residue 287 (Thr287) within the 
regulatory domain of CaMKII (P287-CaMKII) [188, 189]. The presence of this phosphate group 
prevents the auto-inhibitory properties of the enzyme even in the absence of Ca2+. In this 
state, the enzymes activity is unregulated and requires the activity of protein phosphatases to 
de-phosphorylate Thr287 [190]. 
 
In addition to phosphorylation, prolonged activation of CaMKII in an environment of elevated 
ROS leads to the oxidation of methionine residues 281 and 282 M281/282 within the regulatory 
domain (ox281/281-CaMKII) [180]. The oxidative modification of these residues also prevents 
auto-inhibition of the kinase in a similar mechanism to phosphorylation, and the enzyme’s 
activity becomes chronic [180] (Figure 1.12). Since the discovery of phosphorylation and 
oxidation to the enzyme, there have been additional post-translational modifications 
described. These include nitrosylation and O-GlyNAcylation and have similar consequences on 
CaMKII activity [191, 192]. 
 
CaMKII gained significance in the cardiovascular research world after the discovery that this 
chronic activity of CaMKII attributable to post-translational modifications (PTMs), was 
associated with the development of cardiac pathology. Prolonged P287-CaMKII activity has 
been shown to promote hypertrophy in cardiomyocytes [179]. Additionally, increases in the 
phosphorylation status of Ca2+ handling proteins are observed. More specifically, P287-CaMKII 
has been shown to increase the phosphorylation status of the ryanodine receptor 2 (RyR2) 
[193]. This leads to altered Ca2+ handling in cardiomyocytes, leading to impaired contraction, 
a hall mark of heart failure [194]. Alongside phosphorylation, oxidation of CaMKII is linked to 
CVD [180]. Ox281/282-CaMKII is linked to cardiomyocyte apoptosis and arrhythmia [195, 196]. 
Collectively, PTM of CaMKII leading to chronic activity is a mechanism for promoting cellular 










Figure 1.12: Chronic activation of the CaMKII holoenzyme. CaMKII is activated and de-activated by 
the presence and absence of Ca
2+
/calmodulin (CaM), respectively. Prolonged activation of CaMKII 
results in inter-subunit auto-phosphorylation of adjacent subunits within the regulatory domain. In 
addition, chronic activation of the kinase under conditions of elevates oxidative stress leads to oxidation 
of the regulatory domain. Under this chronic activation state driven by phosphorylation and oxidation, 
CaMKII remains active even in the absence of Ca
2+




1.5.3 CaMKII isoform diversity 
 
While chronic activation of CaMKII plays a role in cardiovascular pathology, it is only one small 
part of the CaMKII story. The CaMKII family is diverse and contains four separate genes that 
encode the 4 main isoforms D, E, G and J [184, 185].  CaMKIID and E isoforms are expressed 
in neuronal tissue, whereas the G and J isoforms are ubiquitously expressed. CaMKIIG and J 
are the predominant isoforms expressed in the CVS [197, 198]. 
 
The CaMKIIG isoform family also contains eleven alternatively spliced products under the 
regulation of alternative splicing factor/ pre mRNA splicing factor 2 (ASF/SF2) [197, 199-202]. 
Of the eleven variants discovered, G2, G3 and G6 have been investigated in relation to function 
and pathology. The other cardiovascular isoform CaMKIIJ also contains three splice variants 
1-3, however, no group is yet to investigate any differences between these subtypes [203]. 
 
Sequence homology is highly conserved in the catalytic, regulatory and association domain 
between CaMKIIG variants. However, there is a variable region between the association and 
regulatory domain that is alternatively spliced prior to translation and results in the different  
G variants [200]. There has been evidence to suggest there are functional differences between 
subtypes, best exemplified by the G2 and G3 variants in cardiomyocytes. An early study by 
Srivnovasan et al., (1994) showed that the G2 and G3 subtypes were primarily located in either 
the cytosol or nucleus, respectively. A sequence comparison of the variants showed an eleven 
amino acid insert sequence in the variable region of the G3 subtype which was not present in 
the G2 subtype [204]. The insert sequence contained the lysine-lysine-arginine-lysine (KKRK) 
motif, a well-established nuclear localisation signal (NLS) [205].    
 
Over-expressing CaMKIIG2 in cardiomyocytes results in an increased expression of total 
CaMKIIG in the cytosolic compartment [204].  This is associated with dysfunction of excitation-
contraction coupling due to its phosphorylation effects on the major Ca2+handling proteins 
[206-208]. In contrast, over expressing CaMKIIG3 in cardiomyocytes leads to increased nuclear 
localisation of total CaMKIIG [204]. This was associated with increased hypertrophy of the 
heart through activation of myocyte enhancer factor 2 (MEF-2) GATA-4 and heat shock factor 
1 (HSF-1) transcription factors [209, 210]. In patients with developing heart failure there is an 
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upregulation of the CaMKIIG3 variant [211]. Clearly, both CaMKIIG2 and G3 variants are 
important in the development of cardiac pathology. This suggests that the balance of CaMKIIG 
subtypes in the cytosol and nucleus compartments is critical for cellular homeostasis.  
 
 
1.5.4 CaMKII – an emerging player in vascular disease 
 
Outside the heart in the vasculature, CaMKII is emerging a critical player in health and disease. 
The predominant cardiovascular CaMKII isoforms G and J are expressed in the ECs and VSMCs 
which make up the vascular wall [185, 198, 203]. As a general summary, the literature suggests 
CaMKIIG drives cellular changes that drive the development of vascular pathology [181, 212]. 
Interestingly, in contrast, CaMKIIJ signalling promotes vascular health [213]. 
 
In ECs, CaMKIIG has been shown to phosphorylate NADPH oxidase to increase production of 
the ROS superoxide (O2-x) [214]. Furthermore, in oxidant conditions, CaMKII promotes the 
expression of endothelial nitric oxide synthase (eNOS) [215]. Phosphorylation of eNOS at 
serine residue 1177 (P-eNOS1177) also promotes production of O2-x [216, 217]. We have shown 
in vivo that systemic inhibition of CaMKII results in a reduction of P-eNOS1177 (unpublished 
data, 2017). Alongside an increase in ROS production, CaMKII has been shown to increase EC 
permeability and VCAM-1 expression [212, 218]. Taken together, CaMKII promotes a number 
of cellular changes that promote endothelial dysfunction.  
 
CaMKII isoforms have clear opposing roles in VSMCs. During vascular injury, CaMKIIG 
expression increases and this is associated with increased proliferation and migration of 
VSMCs, evidenced by neo-intimal hyperplasia (the expansion of the tunica intima) [181, 219]. 
A deeper investigation highlighted CaMKIIG2 stimulation of proliferation through the 
activation of the MAPK pathway [181, 219, 220]. In contrast, during vascular injury CaMKIIJ 
expression decreases [181]. As far as physiological roles have been investigated, CaMKIIJ has 
been shown to be involved in ion channel regulation and contraction of VSMC, mediated via 
extracellular signal-related kinase (ERK) and phosphorylation of myosin filaments [213, 221-




In summary, transcriptional regulation of CaMKII generates an extensive isoform family that 
displays a differential pattern of gene expression in different cell types. A limitation of this 
research is that many groups have focused on total CaMKII rather than specific isoforms. 
When conclusions have been drawn in relation to CaMKII function, it is not known whether it 
is the G, J or a combination of isoforms that is/are the main player/s. Identifying the specific 
isoform is important, at least, in the vasculature, where G and J have contrasting roles in 
promoting the synthetic or contractile phenotype, respectively. The pathological effect of the 
CaMKIIG is also observed in the ECs by the increased expression of markers of endothelial 
dysfunction. Thus, CaMKII isoforms play a critical role in vascular health and dysregulation of 











Figure 1.13: Basic summary of CaMKII isoform function in the vasculature. There are four separate 
genes that encode CaMKII isoforms D, E, G and J. The D and E isoforms are predominantly expressed in 
the nervous system and have important roles in brain function. The G and J isoforms are expressed in 
cardiovascular tissue. Furthermore, G has pathological roles in promoting endothelial dysfunction and 
increasing the synthetic phenotype in VSMCs. In contrast, the J isoform has received little attention, 
however it has important functions in VSMC contraction and maintenance of the contractile phenotype. 
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1.6 Rationale, Aims and Hypotheses 
 
Cardiovascular disease (CVD) is the most significant health problem in the developed world. 
In New Zealand, CVD contributes to 33% of annual deaths and continues to burden the health 
care system (Ministry of Health, 2015). The implementation of lipid-lowering therapies 
(statins) has been beneficial in reducing risk for cardiovascular disease (CVD). However, even 
when lipid targets are achieved, there remains a significant residual risk for CVD and surgical 
revascularisation (CABG, PCI) is often required [224]. This is of significance in the Maori 
population, as the Heart Otago data bank shows that Maori undergo coronary artery bypass 
procedures up to 17 years earlier than NZ Europeans. Clearly, there is need for alternative 
therapies to target atherosclerosis in its early stages. 
 
The development of lipid-filled lesions on the inner layer of the arterial wall, is driven by 
pathological changes in ECs, macrophages and VSMCs [13]. CaMKII has been highlighted as a 
nodal signalling protein in EC, macrophage and VSMC physiology and pathology. CaMKIIG and 
J are the predominant isoforms expressed in the cardiovascular system and research suggests 
G has a pathological role under certain disease states, whereas J is protective [181, 212, 213, 
218]. CaMKIIG regulation is complex and alternative splicing results in a differential pattern of 
sub-type expression in different cell groups of the vasculature [200]. While the majority of the 
sequences that encode these sub-types are conserved, there are small differences in the 
variable region which has been shown to display different functions [204]. Since then the 
research field has readily focused on total CaMKII without taking into account the specific 
isoforms and different contributions to functions they may be playing. This is important in 
VSMCs, where G and J may promote the synthetic and contractile phenotype, respectively 
[213, 220]. Regardless, in the studies that have focused on specific isoforms, what is striking 
is that CaMKIIG promotes cellular signalling pathways in ECs and VSMCs that collectively 
contribute to atherosclerosis.  
 
Previously we have showed a systemic inhibition of CaMKII with the inhibitor drug KN-93, 
reduces foam cell lesion development in the ApoE-/- mouse (Figure 1.14). However, this was a 
total blockade of all CaMKII isoforms and did not preserve the important physiological 
functions of CaMKII. In order to better understand CaMKII function, especially in the context 
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of future drug development, it is now required to investigate the specific isoform contributing 




Figure 1.14: CaMKII inhibition in the ApoE mouse reduces foam cell lesion development in the 
brachiocephalic artery. Mice were treated with KN-92 (10µg/kg) or KN-93 (10µg/kg) from 16- to 20 
weeks. Mice were perfusion fixed with PFA and the aortic arch dissected. Longitudinal sections 
containing the brachiocephalic artery were subject to Verhoeffs van Gieson staining for plaque analysis. 
Panels A-B are three representatives of a 20-week brachiocephalic artery after treatment with KN-92 
or KN-93, respectively. Foam cell lesion area including intimal thickening was calculated in the 
brachiocephalic artery by subtracting luminal area from the total brachiocephalic area (C). *P<0.05, 
(n=11) as determined by unpaired Students T-test.  
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The overarching aims of this PhD are to 
 
1. Identify the major isoforms and splice variants of CaMKII in human cells of the 
vasculature and the arteries of atherosclerotic mice (ApoE-/-). (Chapter 2) 
 
2. To knockout the predominant CaMKIIG isoform in ApoE-/- mice and generate the ApoE-
/-CaMKIIG-/- mouse model to identify the contribution of this specific isoform to foam 
cell lesion development. (Chapter 3) 
 
3. To over-express CaMKIIG by AAV, in surgically-ligated carotid arteries of ApoE-/-
CaMKIIG-/- mice to examine the impact of CaMKIIG in foam cell lesion development.  
(Chapter 4) 
 
It was hypothesised that CaMKIIG would be the predominant isoform expressed in the arteries 
of atherosclerotic mice. Furthermore, knock-out of the CaMKIIG isoform in ApoE-/- mice would 
lead to a reduction in total foam cell lesion development. In contrast, overexpressing CaMKIIG 














The following thesis does not contain a general methods chapter. Instead, the protocols 
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The calcium/calmodulin-dependent protein kinase II (CaMKII) family are important regulators 
of cell signalling in normal physiology and disease. CaMKII has four isoforms α, β, δ and γ, each 
encoded by an independent gene. The α and β isoforms are expressed in neuronal tissue and 
have important roles in brain function and learning, whereas δ and γ are more ubiquitously 
expressed [184, 185, 225, 226] [197]. As the focus of the thesis was on atherosclerosis, a 
disease of the arteries, the more ubiquitously expressed CaMKIIδ and γ were the focus of this 
investigation.  
 
CaMKII activity is driven by Ca2+ transients which relieve an auto-inhibitory interaction 
between the regulatory and catalytic domain of the kinase [187]. In this form, CaMKII carries 
out phosphorylation of target substrates for an acute cellular response or a downstream gene 
transcription event [227]. Under conditions of prolonged CaMKII activation, the regulatory 
domain is subject to a number of post-translational modifications (PTMs), including 
phosphorylation, oxidation, nitrosylation and O-GlyNAcylation [180, 188, 189, 191, 192]. 
Importantly, these PTMs are on residues within the regulatory domain, which prevent the 
auto-inhibitory properties of the kinase in the absence of Ca2+, and its activity becomes chronic 
(Section 1.5.2) [180, 188, 228]. Chronically active forms of CaMKII have been associated with 
the development of cardiac pathology [193, 195, 196, 228].  
 
Research into functions of CaMKII within the cardiovascular system has mainly focused on 
total CaMKII, without investigating the specific isoforms δ and γ, that are expressed within the 
cardiovascular system [185, 200, 225]. This is a significant limitation, as subsequent studies 
that did focus on a specific isoform highlighted that CaMKIIδ and γ appear to play opposing 
roles [213, 219-221]. Early studies in the heart demonstrated that it was the δ isoform that 
was the main contributor in driving cardiomyocyte pathology. This ranged from, hypertrophy, 
apoptosis to arrhythmia [195, 196, 211].  
 
Outside the heart in the arteries, CaMKIIδ has been shown to promote vascular pathology. 
CaMKIIδ drives proliferation of VSMCs via the MAPK pathway, a function of the synthetic 
VSMC phenotype [219, 220]. In contrast, the other cardiovascular isoform CaMKIIγ, promotes 
the contractile VSMC phenotype through ion channel regulation and localisation within the 
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contractile apparatus [221-223]. Not only does δ promote dysfunction in VSMC, but also in 
the ECs. More specifically, CaMKIIδ signalling leads to increased adhesive and permeability 
properties of the endothelial wall, a phenotype of endothelial dysfunction [212, 218]. CaMKIIγ, 
has been identified in ECs, however there is no evidence for a function in health and disease 
[185, 198, 203]. So far, the literature would suggest CaMKIIδ promotes vascular disease, 
whereas, CaMKIIγ is protective against vascular disease.  
 
The story is not as simple as two isoforms with two opposing functions in vascular health and 
disease. CaMKIIδ and γ are targeted for post-transcriptional regulation resulting in a subset of 
alternatively spliced isoform variants [197, 204]. There have been eleven CaMKIIδ variants 
described in the literature [200, 202, 211]. Of interest δ2-3 have been shown to have roles in 
hypertrophy, heart failure and restenosis (VSMC proliferation in the intima) [181, 193, 206, 
229]. Moreover, δ6 is involved with thrombin-induced increases in endothelial cell 
permeability [212].  
 
In contrast, CaMKIIγ has three variants identified, however there has been little research into 
any relation to variant-specific functions [198]. Collectively, this suggests it is not only isoforms 
that are important to differentiate apart, but also the splice variants of each isoform. At least 
in the CaMKIIδ variant family there has been evidence to suggest splice variants can display 
different functions [204]. This is best highlighted between the δ2 and δ3 variants, which are 
identical apart from a nuclear localisation signal present within the variable region of the δ3 
variant [204]. This, in turn, primarily locates the δ3 variant to the nucleus whereas the δ2 is 
present in the cytoplasm where they interact with different targets carrying out different 
functions. Clearly, CaMKII regulation is complex and we are only beginning to appreciate the 
importance of investigating isoforms and their splice variants. A growing body of evidence for 
CaMKIIδ functions, compared to CaMKIIγ which has not been extensively studied in the 
context of function, would suggest CaMKIIδ is the most likely contributor to vascular disease 
such as atherosclerosis. 
 
Previously, we have shown that systemic inhibition of CaMKII in ApoE-/- mice leads to a 
significant reduction in foam cell lesion development in the brachiocephalic artery (Figure 
1.14) (unpublished; Worthington, 2016). However, this inhibition blocked the activity of all the 
isoforms and the cumulative physiological role they play. This would include the off target 
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effects in the brain and other nervous tissue. Consequently, a global inhibition of CaMKII is 
not a feasible drug target for the treatment of atherosclerosis. A more detailed investigation 
into the CaMKII isoform family is required for a more targeted strategy to combat the complex 
pathogenesis of atherosclerosis. Therefore, the aim here was to describe the CaMKII isoforms 






Human vascular cells and the atherosclerotic mouse (ApoE-/-) were the models used to identify 
which isoform/s of CaMKII contribute to the pathogenesis of atherosclerosis. Firstly, three 
major cell groups of the vessel wall; human coronary artery smooth muscle cells (HCASMCs), 
human umbilical vein endothelial cells (HUVECs) and human coronary artery endothelial cells 
(HCAECs) were cultured. Additionally, ApoE-/- mice were aged for 13- or 20-weeks, which 
reflect two different stages of atherosclerosis disease pathology. At 13-weeks, the arteries of 
ApoE-/- mice show intimal thickening and small pockets of lesion development. In contrast, at 
20-weeks of age, extensive foam cell lesions present throughout the arterial tree. In this study, 
the aortic arch and carotid arteries were isolated as they are regions prone to atherosclerosis.  
 
Total RNA and protein were extracted from vascular cell cultures and aortic arch/carotid 
artery homogenates (Figure 2.1). RT-PCR was used to demonstrate the mRNA levels of the 
cardiovascular isoforms, CaMKIIG and J. Further to this, RT-PCR was used to identify what 
variants of the CaMKIIG isoforms were present in the human and mouse samples. To validate 
the RT-PCR results, Western blotting (WB) was completed to show total CaMKIIG and J levels 






Figure 2.1: Schematic summary of Chapter 2 methods. The aortic arch and carotid arteries were 
harvested from 13- and 20-week-old ApoE
-/-
 mice. Human umbilical vein endothelial cells (HUVECs), 
human coronary artery endothelial cells (HCAECs) and human coronary artery smooth cells (HCASMCs) 
were cultured. Total RNA and protein were extracted and used for RT-PCR (total CaMKIIG, G1,2,3,6 variants 
and total J) or western blotting (WB) (CaMKIIG and J), respectively. Original figure, Worthington (2020). 
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2.2.1 Cell Culture 
 
Human coronary artery smooth muscle cells (HCASMCs), human umbilical vein endothelial 
cells (HUVECs) and human coronary artery endothelial cells (HCAECs) were cultured in 
specialised growth medium with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin 
(pen/strep) as shown in Table 2.1. 
 
Table 2.1: Cell lines and respective growth media/factors. 
 
Cell Line Media Growth factors 
HCASMC 
(cat.no.C0175C) 














Cells were grown in T75cm2 culture flasks and maintained in an incubator at 37°C with 5% CO2, 
hydrated with milliQ H2O. To sustain each cell line, cells were washed with pre-warmed PBS 
and media changed every 24 hours. Once cells reached 80-90% confluence, they were 
passaged or used for an experiment. All experiments were carried out between passage 
number 4-8. All cell lines were seeded at 5 x 105 cells/ml in 6-well plates for protein and RNA 
extraction. 
 
2.2.2 Animal Work 
 
The apolipoprotein E (ApoE) knockout mouse is the gold standard model for atherosclerosis 
research [154, 160, 162]. ApoE-/- mice on a C57/Bl6 background were housed at the Hercus-
Taieri Research Unit (HTRU) under a 12:12 hr lighting schedule with ad libitum access to food 




Sixteen mixed-sex ApoE-/- mice were randomly assigned into either the 13- or 20-week-old 
group. This sample size was used to provide pilot data on the predominant CaMKII isoform 
involved in early atherogenesis before a more detailed approach. Mice were housed at the 
Hercus-Taieri Research Unit (HTRU) under a 12:12 hr lighting schedule with ad libitum access 
to food and water until 13- or 20- weeks of age.  At the end of the experimental time point, 
mice were euthanised by carbon dioxide (CO2) overdose at a flow rate of 8.5 L/min. Once 
breathing had ceased, mice were left for an additional 2 mins of CO2 and then death was 
confirmed by the pedal withdrawal reflex. Each mouse was weighed and set on a dissection 
board with chest and stomach exposed.  
 
 2.2.2.1 Cardiac Perfusion  
 
The following perfusion was carried out within 10 mins of confirmed death to avoid blood 
clotting. The mouse was sprayed with 70% ethanol. Using a pair of forceps and surgical 
scissors, an incision was made below the sternum to expose the abdominal cavity. The 
diaphragm muscle was carefully blunt dissected away from the ribcage to access the thoracic 
cavity. Either side of the ribcage was cut and folded back in a hinge-like manner to expose the 
heart. The right atria was located by following the superior vena cava to the heart, and cut 
using spring scissors to allow the venous return to drain. Shortly after, a 27 G needle was 
inserted into the left ventricle via the apex of the heart and perfused with 30 ml of heparinised 
PBS (40 U/ml).  
 
The aortic tree was cut out of the mouse and set under a dissection stereomicroscope (Motic 
Ltd, Hong Kong, China) (Figure 2.2). The carotid arteries were identified and isolated off the 
aortic arch using micro spring scissors. The carotid arteries and aortic arch were further 
divided into four segments. One piece of the divided carotid and aortic arch samples was 
stored for RNA extraction while the other three segments were stored for protein extraction. 












Figure 2.2: Intact aortic arch (A) in the chest cavity and (B) dissected. ApoE-/- mouse was perfusion 
fixed with 40U/ml heparinised PBS and 50 ml 4% PFA. Excess adipose tissue was carefully trimmed 
away from the aortic arch and associated branches using a pair of micro spring scissors under a 
stereomicroscope (A). The aortic tree was dissected from mouse and set under a microscope to isolate 
vessels (B). Red arrows indicate the anatomy of the aortic tree. Right common carotid artery (RCA), left 
common carotid artery (LCA), brachiocephalic artery (BA), aortic arch, right subclavian artery (RSA), 




2.2.3 RT-PCR and Gel Electrophoresis 
 
Total RNA was extracted from human cells (HCASMCs, HUVECs, HCAECs) and the aortic arch 
and carotid arteries of ApoE-/- mice using TRIZOL reagent (Sigma-Aldrich, Munich, Germany). 
Total RNA concentration was quantified by measuring absorbance at 260/280 nm using the 
Maestro nanodrop (MaestroGen Inc, Taiwan). 1 µg RNA was reverse transcribed using the 
SuperScriptVILO cDNA Synthesis Kit (ThermoFisher Scientific, Waltham, USA, cat.no. 
11754050) as shown in Table 2.2.  
 
Table 2.2: Reverse transcription protocol. 
Reagent Volume/reaction Reaction 
5X ViLO reaction mix 4 µL 25°C, 10 mins 
42°C, 60 mins 
85°C, 5 mins 
 
10X Superscript (ViLO) 
enzyme mix 
2 µL 
RNA 1 µg 
DEPC – treated H2O Adjusted to total volume of 20 
µL 
 
100 ng of cDNA was used for RT-PCR using the KAPA HiFi HotStart ReadyMix (Cape Town, 
South Africa). The reaction components are described in Table 2.3. A list of primers used for 
respective human (Hu) and mouse (Ms) species and target products are provided in Table 2.4. 
Primers were either designed for this project or obtained from the scientific literature [212]. 
PCR amplification was performed in a thermal supercycler (Kyratec, Queensland, Australia). A 
no template control (NTC) was performed for each RT-PCR experiment where cDNA was 
replaced with DEPC-water. This was to control for any contaminating DNA that may be present 
in the other components of the PCR reaction mix. GAPDH was used as the reference gene for 
RT-qPCR and WB as it is routinely used in our lab as a stable house-keeping gene under disease 
conditions.  
 
Table 2.3: PCR mastermix reaction. 
Reagent Volume/reaction (µL) 
KAPA HiFi Hot Start Ready Mix (KAPA 
Biosystems, cat.no. KRO370) 
12.5 
Forward primer 0.75 
Reverse primer 0.75 
DEPC-treated H2O 9 
cDNA 2 (100 ng) 
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Table 2.4: Primer sequences and cycling conditions for human cells and mouse arteries. 
Primer Sequence Cycling  
 
Target Size 
MsCaMKIIG   
 





















































































R 5’-CACCAGGAGGATATACAGGA-3’  
HuGAPDH  
 






R 5’-GCGCCCAATACGACCAAATC-3’  
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Agarose gels were used for electrophoresis to separate and visualise PCR products. Gels 
ranged from 1-4% agarose in TAE buffer (40mM Tris, 20mM acetate, 1mM EDTA (Calbiochem, 
San Diego, USA, cat.no. 16G145210)) depending on the number and size of target products. 
The gel was microwaved to dissolve agarose and left to cool before adding 6 µL of SYBR safe 
DNA stain (ThermoFisher, cat.no. S33102). The gel was poured into the tray and left to cool. 
Products of PCR reactions were mixed with BlueJuice Gel Loading Buffer (10X) 
(ThermoFisher Scientific, cat.no. 10816015) and loaded onto an agarose gel alongside the 
NTC. The size of each amplified product was confirmed by comparing with a 100 kb DNA 
marker (ThermoFisher, cat.no. 15628050) that was electrophoresed in parallel with samples. 
For primer pairs with one target, a low percentage agarose gel (1-2%) was used with 
electrophoresis at 100 V for 2 hr. In contrast, for primer sets that amplify a number of products 
of different sizes, a higher percentage agarose gel was used (2.5-4%) for electrophoresis at 60 
V for 2 hr. Agarose gels were placed in the tray of the PXi 4 Touch Multi-Application Gel 
Imaging System (Syngene, PXi 4 Touch, Bangalore, India) and images digitally captured. 
 
2.2.4 Western Blots 
 
Total protein was extracted using RIPA lysis buffer (50 mM Tric-HCl, 150 mM NaCl, 0.1% SDS, 
1% Triton X-100, 1 mM EDTA, milliQ H2O, pH 7.4). 40 µg samples were mixed with Bolt LDS 
sample buffer (4X) (ThermoFisher, cat.no. B0007) and Bolt reducing agent (10X) 
(ThermoFisher, cat.no. B0004) and heated at 70°C for 10 mins. Denatured samples were then 
loaded in a 10% Bolt Bis-Tris Plus Gel (Invitrogen, Carlsbad, USA, cat.no. NW00105) alongside 
the SeeBlue Plus 2 Pre-stained Protein Standard (Invitrogen, cat.no. LC5925). The gel tank 
was plugged into the power pack and electrophoresis performed at 150 V for 90 mins. 
 
The gel was placed on a piece of PVDF membrane and sandwiched between four pieces of 
blotting paper. The transfer sandwich was submerged in transfer buffer (25 mM Tris, 0.2 mM 
Glycine, 10% methanol) in a Mini-PROTEAN Tetra Cell (Biorad, Hercules, USA) system. The tank 
was connected to a power pack and 90 V was applied for 90 mins to transfer proteins from gel 
to PVDF membrane. After transfer, the PVDF membrane was removed and blocked in 5% milk 
powder in TBST (10 mM Tris, 100 mM NaCl, 5% Tween 20) for 1 hr. The membrane was then 
probed with primary and secondary antibodies as shown in Table 2.5. Primary antibodies were 
added to the membrane and incubated overnight at 4°C. The following day, membranes were 
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washed in 5 min intervals for 30 min with TBST. Secondary antibodies were then incubated 
for an hour and washed with TBST in a similar manner. Supersignal West Pico 
Chemiluminescent Substrate (ThermoFisher, cat.no. 34087) was used to detect conjugated 
secondary antibody and imaging of the membrane was performed using the Syngene PXi 4 
Touch. 
 
Table 2.5: Primary and secondary antibodies with respective dilutions. 
Primary Antibody Dilution Factor  Secondary Antibody Dilution Factor 
CaMKIIδ 
(ThermoFisher 
Cat. No. PA5-22168) 
1:3500 Goat anti-rabbit HRP 







GAPDH (GeneTex®  
Cat. No. GTX627408) 
1:7000 Goat anti-mouse HRP 





2.2.5 Statistical Analysis 
 
All data was analysed on GraphPad Prism 8 and expressed as mean r SEM. Significant 
differences were determined by Students T-Test or 2-way ANOVA with Tukey’s multiple 
comparisons post-hoc test. Significant (*p<0.05, ****p<0.0001) and non-significant (NS) 






2.3.1 CaMKIIG mRNA levels in the aortic arch and carotid arteries of 13- and 20-week old 
ApoE-/- mice. 
 
CaMKIIG is suggested to be the pathological isoform that contributes to vascular disease [181, 
212, 218, 219]. To show the relative mRNA levels of CaMKIIG during the progression of 
atherosclerosis, the aortic arch and carotid arteries of 13- and 20-week-old ApoE-/- mice were 
dissected (Figure 2.3). The homogenates will contain all cell groups of the vascular wall 
including endothelial cells, smooth muscle cells and foam cells (macrophages). Total RNA was 
extracted and RT-PCR targeting the total MsCaMKIIG and MsV2 (CaMKIIG1,2,3,6) [212] primer 
sets were completed in a thermocycler. PCR products were visualised by agarose gel 
electrophoresis (Section 2.2.3). 
 
Figure 2.4 shows the relative mRNA level of CaMKIIG in the aortic arch of 13- and 20-week-old 
ApoE-/- mice. The presence of a band at 150 bp in each sample lane is indicative of the CaMKIIG 
product (NM_001025438). The faint band below 150 bp is likely to be primer dimer as the same 
band is present in the no-template control (NTC). 
 
 
CaMKIIG mRNA was detected in the aortic arch of 13- and 20-week ApoE-/- mice. Next, it was 
identified what specific G variants are present. Figure 2.5 shows the products of MsV2 
(CaMKIIG1,2,3,6) [212] targeted primers in the aortic arch of 13- and 20-week ApoE mice. The 
presence of bands at 227 bp and 316 bp are indicative of a combination of either the G1/3  or 
G2/6 variants, respectively. CaMKIIG1,2,3,6 variants were present before the onset of lesion 
development in the aortic arch of 13- week ApoE-/- mice. Furthermore, the same variants were 














Figure 2.3: Dissected aortic tree of a 20-week ApoE-/- mouse. The mouse was euthanised by CO2 
overdose at 20-weeks of age. The mouse was fixed with 4% PFA via cardiac perfusion. The aortic tree 
with carotid arteries were dissected out. The carotid artery and aortic arch were isolated and snap 
frozen in liquid N2. Red arrows indicate the anatomy of the aortic arch. Photo taken on a 
stereomicroscope (10X objective). Representative image of one aortic tree from a 20-week ApoE
-/-
 





Figure 2.4: DNA agarose gel showing total CaMKIIG levels in the aortic arch of 13- and 20-week ApoE-
/- mice. Total RNA was extracted and 100 ng cDNA was used in RT-PCR targeting the total MsCaMKIIG 
primer set. PCR products were loaded onto a 1.5% agarose gel and electrophoresis run at 100 V for 1 
hr. GAPDH was used as a reference gene. No template control (NTC) contains reaction mix with DEPC-
H2O replacing DNA sample. 100 bp DNA marker (Invitrogen cat.no. 15628019). Representative gel 




Figure 2.5: DNA agarose gel showing CaMKIIG variant levels in the aortic arch of 13- and 20-week 
ApoE-/- mice. Total RNA was extracted and 100 ng cDNA was used in RT-PCR targeting the MsV2 primer 
set. PCR products were loaded onto a 3.5% agarose gel and electrophoresis run at 60 V for 2 hr. GAPDH 
was used as a reference gene. No template control (NTC) contains reaction mix with DEPC-H2O 
replacing DNA sample. 100 bp DNA marker (Invitrogen cat.no. 15628019). Representative gel shows 
data for 3 of 8 independent mice from each age group (n = 8).  
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To validate these observations,  CaMKIIG and its spliced variants were also measured in the 
carotid artery. Figure 2.6 shows CaMKIIG is present in the carotid arteries of 13- and 20-week 
ApoE-/- mice, evidenced by the presence of a band at 150 bp. Figure 2.7 shows the relative 
level of CaMKIIG variants in the carotid arteries of 13- and 20-week ApoE-/- mice. The presence 
of bands at 227 bp and 316 bp are indicative of a combination of the G1/3 and G2/6 variants. 
Therefore, like the aortic arch, CaMKIIG1,2,3,6 are expressed in the carotid artery of 13- and 20-





Figure 2.6: DNA agarose gel showing total CaMKIIG levels in the carotid arteries of 13- and 20-week 
ApoE-/- mice. Total RNA was extracted and 100 ng cDNA was used in RT-PCR targeting total MsCaMKIIG 
primer set. PCR products were loaded onto a 1.5% agarose gel and electrophoresis run at 100 V for 1 
hr. GAPDH used as a reference gene. No template control (NTC) contains reaction mix with DEPC-H2O 
replacing DNA sample. 100 bp DNA marker (Invitrogen cat.no. 15628019). Representative gel shows 




Figure 2.7: DNA agarose gel showing CaMKIIG variant levels in the carotid arteries of 13- and 20-
week ApoE-/- mice. Total RNA was extracted and 100 ng cDNA was used in RT-PCR targeting the MsV2 
primer set. PCR products were loaded onto a 3.5% agarose gel and electrophoresis run at 60 V for 2 hr. 
GAPDH was used as a reference gene. No template control (NTC) contains reaction mix with DEPC-H2O 
replacing DNA sample. 100 bp DNA marker (Invitrogen cat.no. 15628019). Representative gel shows 
data for 3 of 8 independent mice from each age group (n = 8).  
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2.3.2 CaMKIIG mRNA levels in the human vascular cell.  
 
Results so far have shown that CaMKIIG mRNA is present in the arteries of ApoE-/- mice during 
the progression of atherosclerosis. In particular, CaMKIIG1,2,3,6 variants were detected by RT-
PCR. To determine whether the variants in the ApoE-/- mouse are the same as those found in 
human vascular cells, CaMKIIG variant levels were analysed in HUVECs and HCASMCs using the 
huV1 and huV2 primer set(s) [212]. The huV1 primer set is specific for CaMKIIG2 and G6 
variants, whereas the huV2 primer set is specific for CaMKIIG1, G2, and G3 [212].  These cell 
models are commonly used for studying endothelial and smooth muscle cell physiology [35, 
39, 48, 212, 220, 230, 231]. 
 
Figure 2.8 shows CaMKIIG variant levels in HUVECs and HCASMCs. For the huV1 targeted PCR 
primer set, the presence of a band at 130 bp or 190 bp indicates the CaMKIIG2 and G6 variants, 
respectively. For the huV2 targeted RT-PCR, the presence of a band at 229 bp, 275 bp and 350 
bp shows the CaMKIIG2, G1, and G3 variants, respectively. In HUVECs and HCASMCs CaMKIIG1,2,3  
variants were detected. Furthermore, HCASMCs had a faint band at the 190bp marker 







Figure 2.8: DNA agarose gel showing CaMKIIG variant levels in human cells of the vasculature. Total 
RNA was extracted from HUVECs and HCASMCs. 100 ng cDNA was used in RT-PCR targeting CaMKIIG 
variants with huV1 and huV2 primer sets. PCR products were loaded onto a 2.5% (huV1), 4% (huV2) 
and 1% (GAPDH) agarose gel and electrophoresis run at 60 V for 2 hr. GAPDH was used as a reference 
gene. No template control (NTC) contains reaction mix with DEPC-H2O replacing DNA sample. 100 bp 
DNA marker (Invitrogen cat.no. 15628019). Representative gel shows data for 3 of 6 independent 
HUVEC and HCASMC experiments (n = 6).  
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2.3.3 CaMKIIJ mRNA Levels in human and mouse vascular cells.  
 
So far, it has been shown that CaMKIIG mRNA is present in cultured human ECs, VSMCs and 
the atherosclerotic aortic arch and carotid arteries of ApoE-/- mice. In particular CaMKIIG1,2,3,6 
variants were detected in extracts from both human vascular cells and the arteries of ApoE-/- 
mice. However, CaMKIIG is not the only isoform specific to the vasculature. CaMKIIJ is the 
other predominant isoform expressed in the vasculature [203] and has been shown to play a 
contrasting protective role against vascular disease [181, 213]. Therefore, it was next 
determined what the CaMKIIJ mRNA levels were in ECs and VSMCs and the aortic arch of 
ApoE-/- mice.  
 
Figure 2.9 shows the relative mRNA level of CaMKIIJ in the aortic arch of 13- and 20-week 
ApoE-/- mice. CaMKIIJ was detected before and during the development of atherosclerosis 
indicated by the presence of a band at 150 bp in the 13- and 20-week sample lanes. Figure 
2.10 shows the relative mRNA level of CaMKIIJ in HUVECs and HCASMCs. The presence of a 





Figure 2.9: DNA agarose gel showing total CaMKIIJ isoform levels in the aortic arch of 13- and 20-
week ApoE-/- mice. Total RNA was extracted and 100 ng cDNA was used in RT-PCR targeting CaMKIIJ. 
PCR products were loaded onto a 1.5% agarose gel and electrophoresis run at 100 V for 1 hr. GAPDH 
was used as a reference gene. No template control (NTC) contains reaction mix with DEPC-H2O 
replacing DNA sample. 100 bp DNA marker (Invitrogen cat.no. 15628019). Representative gel shows 




Figure 2.10: DNA agarose gel showing total CaMKIIJ isoform levels in human cells of the vasculature. 
Total RNA was extracted from HUVECs and HCASMCs. 100 ng cDNA was used in RT-PCR targeting 
CaMKIIJ. PCR products were loaded onto a 1.5% agarose gel and electrophoresis run at 100 V for 1 hr. 
GAPDH was used as a reference gene. No template control (NTC) contains reaction mix with DEPC-H2O 
replacing DNA sample. 100 bp DNA marker (Invitrogen cat.no. 15628019). Representative gel shows 
data for 3 of 6 independent HUVEC and HCASMCs experiments (n = 6). 
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2.3.4 CaMKIIG and J protein levels in human and mouse vascular cells. 
 
The CaMKIIIG and J isoforms are expressed in human ECs, VSMCs, and the aortic arch and 
carotid arteries of ApoE-/- mice at the mRNA level. To identify whether the transcript level 
extends to protein expression, human cells were cultured and lysates subject to Western 
blotting (WB) targeting CaMKIIIG and J. HUVECs were used in previous experiments as they 
are a validated EC model, however, to more closely represent the coronary artery, for the next 
set of experiments, human coronary artery endothelial cells (HCAECs, Sigma Aldrich, 300-05a)  
were obtained from a commercial source. HUVECs were compared HCAECs to confirm the 
similarity of EC CaMKII isoform expression.  
Figure 2.11A shows CaMKIIG expression in HUVECs, HCAECs and HCASMCs evidenced by the 
presence of a band indicated by the blue arrow above the 49 coda marker. The HUVEC and 
HCAEC mean band intensities were pooled as representative of EC and compared with 
HCASMC. GAPDH was used as a loading control to account for any global protein expression 
differences between cell groups, as well as total protein concentration differences. The band 
intensity for CaMKIIG in HCASMC groups was visually stronger that the endothelial cell groups 
(N.S, n = 3) (Figure 2.11B).  
CaMKIIJ expression was also detected in vascular endothelial cells and HCASMCs indicated by 
the presence of a band above the 49 coda, indicated by the blue arrow (Figure 2.12A). The 
other faint bands present may be non-specific targets or other CaMKII isoforms. Unlike the 
different CaMKIIG expression pattern observed between ECs and HCASMCs, here, CaMKIIJ 
expression was relatively similar between cell types (N.S, n=3)(Figure 2.12B). The high SEM in 








Figure 2.11: Western blot membrane showing CaMKIIG and GAPDH protein levels from human cells 
of the vasculature (A). Quantification of CaMKIIG in vascular endothelial cells (ECs) and human 
coronary artery smooth muscle cells (HCASMCs) (B). Protein lysates were extracted from HUVECs, 
HCAECs and HCASMCs. 40 µg samples were subject to PAGE electrophoresis for 1 hr. Proteins were 
transferred to a PVDF membrane, blocked and incubated with antibodies targeting CaMKIIG and 
GAPDH. Bands were detected using the Super signal West Pico Chemiluminescent Substrate 
(ThermoFisher, cat.no. 34087) and digital images captured on a Syngene PXi 4 Touch. The positions of 
the kDa marker weights are shown to the left (ThermoFisher, cat.no. 15628050) (A). Histograms show 











Figure 2.12: Western blot membrane showing CaMKIIJ and GAPDH protein levels from human cells 
of the vasculature. Quantification of CaMKIIJ in endothelial cells (ECs) and human coronary artery 
smooth muscle cells (HCASMCs) (B).  Protein lysates were extracted from HUVECs, HCAECs and 
HCASMCs. 40 µg samples were subject to PAGE electrophoresis for 1 hr. Proteins were transferred to 
PVDF membrane, blocked and incubated with antibodies targeting CaMKIIJ and GAPDH. Bands were 
detected using the Supersignal West Pico Chemiluminescent Substrate (ThermoFisher, cat.no. 34087) 
and digital images captured on a Syngene PXi 4 Touch. The positions of the kDa marker weights are 
shown to the left (ThermoFisher, cat.no. 15628050) (A). Histograms show mean band densitometry 
level r S.E.M (n = 3)(B). Non-significant (N.S) as determined by Students unpaired T-test. 
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CaMKIIG and J expression was detected in human cells of the vasculature. Furthermore, G 
levels were greater in HCASMCs compared to ECs. Next, it was tested which isoform of CaMKII 
was dominantly expressed in the vasculature of ApoE-/- mice throughout the development of 
atherosclerosis. Western blot analysis was used to target CaMKIIG and J in aortic arch 
homogenates of 13- and 20-week old ApoE-/- mice. 
 
CaMKIIG  expression levels were detected at 13-weeks indicated by the strong band above the 
49 markers as indicated by blue arrow (Figure 2.13). CaMKIIG levels remained high at 20-weeks 
and no changes were seen when compared to densitometry of 13-weeks data. Compared to 
CaMKIIG, CaMKIIJ expression levels were lower as evidenced by faint bands above the 49 kDa 
marker (p<0.0001). At 20-weeks, CaMKIIJ levels remained low (N.S, ANOVA, n=7) (Figure 
2.13B). Collectively, this data indicates that CaMKIIG is the most likely isoform that is driving 




Figure 2.13: CaMKIIG is the predominant isoform present in the vasculature of ApoE-/- mice. Protein 
lysates were extracted from the aortic arch of 13- and 20-week od ApoE
-/-
 mice.  40 µg samples were 
subject to PAGE electrophoresis for 1 hr. Proteins were transferred to a PVDF membrane, blocked and 
incubated with antibodies targeting CaMKIIG, CaMKIIJ  and GAPDH. Bands were detected using the 
Supersignal West Pico Chemiluminescent Substrate (ThermoFisher, cat.no. 34087) and digital images 
captured on a Syngene PXi 4 Touch. The positions of the kDa marker weights are shown to the right 
(ThermoFisher, cat.no. 15628050) (A). Representative blot showing five out of seven independent mice 
for 13-week and 20-week age groups. Histograms below show mean band densitometry level r S.E.M 
(n=7) (B).****P<0.0001, non-significant (N.S),  as determined by two-way ANOVA with Tukey’s multiple 




A molecular approach has been used employing RT-PCR and Western blotting to identify what 
isoform of the CaMKII family was the most likely key player in early atherogenesis. An 
investigation of CaMKII isoform expression in human ECs and VSMCs, and aortic arch/carotid 
artery tissue from a mouse model of atherosclerosis (ApoE-/-) identified CaMKIIδ as the 
predominant isoform.  
 
The two regions of the aortic tree selected for investigation in the ApoE-/- mouse was the aortic 
arch and carotid arteries. These regions are prone to the development of extensive 
atherosclerosis, and at 20-weeks of age in the ApoE-/- mouse, both regions have reported foam 
cell lesions [160, 162, 172].  CaMKIIδ mRNA was expressed in the aortic arch and carotid 
arteries of ApoE-/- mice as well as cultured HUVECs and HCASMCs (Section 2.3.1-2). Other 
observational and mechanistic studies that have focused on a specific CaMKII isoform have 
identified the δ form as the predominant type expressed in the cells of the heart and 
vasculature [185, 197, 200]. Activation of CaMKIIδ has been identified in promoting EC 
dysfunction and a proliferative response of VSMCs [212, 219, 220]. This finding is important 
because endothelial dysfunction and VSMC proliferation are key contributing mechanisms in 
the development of foam cell lesions [13].  
 
Given that δ was the dominant isoform, it was next investigated what splice variants of 
CaMKIIδ were present. Identifying the specific variants is important as in previous research it 
has been shown at least in cardiomyocytes, the δ2 and δ3 types display different functions due 
to differential localisation to the cytoplasm and nucleus, respectively [204, 229]. CaMKIIδ 
variants 1, 2, 3 and 6 were present in HUVECS and HCASMCs, as well as in the aortic arch and 
carotid arteries of ApoE-/- mice. What seemed to stand out across each experiment and be 
consistent between species was the CaMKIIδ2 variant (Section 2.3.1-2). The specific CaMKIIδ2 
has already been identified in the development of cardiac disease and more recently, in the 
vasculature it is emerging a player in vascular pathology [181, 193, 229].  CaMKIIδ2 is involved 
in proliferation of VSMCs, a key event in the development of foam cell lesions [219, 220]. 
While the CaMKIIδ2 was becoming the variant of increasing interest in atherogenesis, the 
similar mRNA profile of variants between species was important in further validating the ApoE-
/- mouse for atherosclerosis research in a translational aspect. For the purpose of these 
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observational pilot GAPDH was a suitable reference gene. In future studies it would be useful 
to use a combination of reference genes as GAPDH expression levels have been shown to 
fluctuate under certain conditions [232]. 
 
Of interest, CaMKIIδ6 mRNA was detected in ApoE-/- mice but it was only just observable in 
HUVECs and HCASMCs after overexposing the agarose gel (Figure 2.8). This is likely to reflect 
differences in the local environment between the two models. In the arteries of ApoE-/- mice, 
ECs and VSMCs are exposed to inflammation (atherosclerosis) and the physical forces 
associated with blood flow (shear stress) [26, 34]. In contrast, human cells were cultured 
under standard non-inflammatory conditions. An increase in CaMKIIδ6 has been shown to be 
involved in increasing the permeability of the endothelial wall, a common phenotype of 
endothelial dysfunction and atherosclerosis [212]. The lack of cell culture conditions that 
mimicked an atherosclerotic milieu is a probable reason for the lack of CaMKIIδ6 transcript. In 
a future experiment it would be interesting to investigate whether exposing HUVECs and 
HCASMCs to an inflammatory milieu with TNF-D and H2O2 would induce CaMKIIδ6 
transcription. 
 
The major difference between the cell culture and animal model is that the individual vascular 
cells were investigated in humans, whereas aortic arch and carotid artery homogenates of the 
ApoE-/- mouse contained a combination of ECs, SMCs and any other immune cells that are 
present in the vascular wall. This meant that in the human cell cultures, CaMKIIδ and γ 
expression was observed in individual ECs and VSMCs. In contrast, CaMKIIδ and γ expression 
profile in artery homogenates from ApoE-/- mice is the cumulative expression profile from ECs, 
VSMCs and foam cells (macrophages). However, for the purpose of this study, the primary 
objective was to identify the predominant isoform likely contributing to atherosclerosis rather 
than what cell group was the main contributor. 
 
CaMKIIδ protein expression was significantly higher than γ expression in the arteries of ApoE-
/- mice at both 13- and 20-weeks (Figure 2.13). These two time points reflect two different 
stages in the disease progression of atherosclerosis, a pre-lesion phase (13-weeks) and lesion 
phase (20-weeks) [162]. While CaMKIIδ expression was high at 13-weeks, the levels persisted 
at 20 weeks and no differences were observed. The hypothesis of this study was that CaMKIIδ 
was the most likely isoform expressed in vascular cells and the most likely player contributing 
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to the pathogenesis of atherosclerosis. Therefore, this result was surprising as it was 
anticipated that δ expression levels would increase with disease progression. Firstly, this 
suggests the 13-week time point was not early enough in the disease progression. At 13-weeks 
ApoE mice already present with ED and small pockets of intimal lipid accumulation [162]. If 
there is an increase in CaMKIIδ expression, it could be occurring at a time before there are any 
gross changes to the vascular wall. Secondly, if CaMKIIδ expression is not changing then the 
activation state of the enzyme could be. In previous work, our lab showed that the level of 
P287-CaMKII increases over this lesion growth phase (Unpublished; Worthington 2016). This 
activated form of CaMKII has been well-established in the development of cardiovascular 
pathology [178, 180, 228].  
 
The individual cell groups that compose the vascular wall of ApoE-/- mice were not investigated 
for their relative contribution to CaMKIIδ expression and potentially atherosclerosis. However, 
pilot data can be provided from the human cell culture studies. HCAECs, HUVECs and 
HCASMCs were cultured and analysed for CaMKIIG by WB. Across cell groups, HCASMC had 
saturated CaMKIIG expression compared with EC samples (Figure 2.11). This was not 
significant due to a low n-number and densitometry saturation, which is likely to be masking 
a more dynamic range. Regardless, these three experiments provided enough observational 
data that δ was the dominant CaMKII isoform in VSMCs.  
 
While it was becoming increasingly evident that CaMKIIδ is the predominant isoform 
expressed and the most likely player in atherogenesis, it is important to reflect on the other 
major isoform present in the vasculature [225]. In our cell culture model gamma expression 
was observed in HCAECs, HUVECs and HCASMCs (Figure 2.10). For mouse arterial tissue, 
CaMKIIγ expression levels were low at 13-weeks, compared with the δ isoform levels, and 
expression remained low at 20-weeks (Figure 2.9). In contrast with CaMKIIδ, CaMKIIγ been 
shown to be protective against vascular disease [213, 221]. In VSMCs that make up majority 
of vascular wall, CaMKIIγ protects against vascular pathology by promoting the contractile 
phenotype. This is achieved via regulation of critical ion channels and the specific isoform 
localisation within the contractile machinery of VSMC [221-223]. In the context of an 
atherosclerotic model, it is therefore not unexpected that the leveI of CaMKIIγ is relatively 
low. As discussed previously, CaMKIIδ expression may increase earlier than any visible lesion 
growth. In turn, there may be a dramatic drop in gamma prior to the development of foam 
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cell lesions. If this is the case and there is an increase in the “pathological” delta isoform 
alongside a drop in the “protective” gamma isoform, then this would be a double edged sword 
in lesion development. The gamma isoform clearly warrants future investigation as a 
protective mechanism. 
 
In summary, the results observed in this chapter showed that CaMKIIδ is the major isoform 
present in vascular tissue and a likely player in atherosclerosis. Furthermore, RT-PCR analysis 
at the transcript level revealed that between both mouse and human species CaMKIIδ 1, 2, 3 
and 6 variants are present. Now it has been identified that human vascular cells and artery 
homogenates of ApoE-/-  mice express the same splice variants, the investigation can continue 
in the ApoE-/- mouse that encompasses all the physiological/pathological variables of 
atherosclerosis. Also the similar expression profile across species is of interest in a 
translational aspect for drug target discovery. To advance our understanding of the 
contribution of CaMKIIδ in foam cell lesion development, an ApoE-/- model is required that has 
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The calcium/calmodulin-dependent protein kinase II (CaMKII) family is comprised of four 
isoforms, D, E, G and J as well as associated splice variants [184, 185, 197]. The isoforms are 
differentially expressed in the tissues of the body. CaMKII carries out cellular signalling by 
phosphorylation of target proteins and has emerged a critical regulator of cell signalling in 
health and disease. 
 
The CaMKIID and E isoforms are predominantly expressed in the brain and nervous tissue 
[184]. Studies have shown these isoforms play critical roles in synaptic plasticity and neuro-
physiological processes such as long term potentiation (LTP) [233-235]. In the cardiovascular 
system (CVS), the predominant isoforms expressed are the G and J type [197, 198]. 
Interestingly, the G isoform has been associated with the development of cardiovascular 
pathology, whereas, J has been shown to promote vascular health [181, 213]. 
 
CaMKIIG has been shown to be important in the regulation of Ca2+ handling proteins as well 
as the regulation of inflammatory and survival pathways [175, 227]. CaMKIIG has an important 
physiological role in mediating E-adrenergic stimulation. This is best exemplified in the heart 
where CaMKIIG mediates E-adrenergic signalling by the phosphorylation of key Ca2+ handling 
proteins to improve contraction of the heart [175, 178]. However, prolonged activation of the 
kinase has emerged as driver of cellular dysfunction and cardiovascular pathology [195, 196]. 
Increasing evidence for CaMKIIG would suggest the compounding pathological effects of the 
kinase in cardiovascular pathology outweigh any main physiological effect, which is a key 
consideration for drug discovery and development.  
 
CaMKIIG is expressed in ECs and VSMCs, which are the main cell types that compose the artery 
wall [185, 200]. Like the heart, CaMKIIG has been associated with the development of cellular 
pathology. In ECs, CaMKIIG promotes phenotypes of endothelial dysfunction by increasing 
permeability and expression of adhesion molecules e.g. VCAM-1 [212, 215, 218].  
Furthermore, in VSMCs, CaMKIIG promotes the synthetic phenotype by the stimulation of 
migration and proliferation pathways in a number of in vivo and in vitro approaches [181, 219, 
220]. In contrast, the other cardiovascular isoform CaMKIIJ has been shown to oppose this 
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synthetic function by promoting contraction of VSMCs [181, 213]. This is through the 
regulation of specific ion channels and localisation around myosin filaments [221-223]. 
Collectively, this suggests CaMKIIG promotes vascular pathology whereas, CaMKIIJ is 
protective. 
 
Still, many of the studies that have investigated CaMKII in the vasculature lack detail about 
what specific isoform is being targeted so many of these functions remain incompletely 
understood. The effects of CaMKIIG  on EC and VSMC dysfunction are common mechanisms 
in the pathogenesis of atherosclerosis, however CaMKII signalling has not been investigated 
in a model of atherosclerosis. To further understand CaMKIIG  function in atherosclerosis, a 
specific genetic approach is required in a model of atherosclerosis such as the ApoE-/- mouse.  
 
The ApoE-/- mouse is the gold standard model used for atherosclerosis research. This mouse 
model contains a knockout in the apolipoprotein E (ApoE) gene, essential for cholesterol 
metabolism and transport. ApoE-/- mice develop elevated plasma LDL-C levels and develop 
atherosclerotic lesions throughout the aortic tree [160]. The ApoE-/- mice generally develop 
atherosclerosis in the aortic sinus, aortic arch and brachiocephalic artery whereas, in humans, 
the disease tends to manifest in the coronary and carotid arteries [162, 165, 171]. What is 
important though is that between species the lesions develop with a similar phenotype and 
physiology to human [162, 172]. This includes intimal thickening, foam cell lesions, lipid 
deposits and later in the disease progression, a necrotic core and calcification.  
 
Interestingly, male ApoE-/- mice are more resistant to the development of atherosclerosis than 
females. This sex difference is observed over a number of genetic backgrounds for ApoE 
models, including the C57/Bl6-ApoE-/- which is commonly used in our lab and others in the 
atherosclerosis research world [236-238]. For example, lesion content in the aortic sinus of 
female ApoE-/- mice on a C57/Bl6 background is more developed than males at 20-weeks age 
[239]. The mechanisms that promote this sex difference are not fully understood and many 
labs are investigating how the genetic component of ApoE gene may influence this. One 
thought, is that the anti-atherogenic particle HDL concentration is higher in males than 
females so protection may be conferred here [236]. Regardless of these differences in disease 
timeline, both male and female mice display atherosclerotic lesions with a similar physiology 
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to humans and remain a great model for investigating the pathogenesis of atherosclerosis 
[162, 172].  
 
Previously, we have shown that a systemic inhibition of CaMKII in ApoE-/- mice leads to a 
significant reduction in foam cell lesion development in the brachiocephalic artery. While 
CaMKII clearly plays a role in lesion progression the isoform family is extensive. Furthermore, 
a global inhibition of CaMKII is not feasible as a clinical target with the physiological roles other 
isoforms play in the other systems of the body. For this reason, it is important that the critical 
subtype(s) of CaMKII which plays a role in atherosclerotic disease pathology is identified.  
 
In Chapter 2, we saw that CaMKIIG was the predominant isoform expressed in cell of the 
human and mouse vasculature. Furthermore, during the development of atherosclerosis 
CaMKIIG expression was relatively high in contrast to CaMKIIJ, and levels persisted with 
disease progression. This suggests from an observational point, that it is the CaMKIIG isoform 
most likely contributing to atherosclerosis, but to answer this, a mechanistic study is required 





In order to investigate the specific role of CaMKIIG in atherosclerosis, there needed to be a 
model that blocked CaMKIIG expression while keeping the other isoforms D, E, and J intact. 
For this work, a good mouse model would be a CaMKIIG knockout (KO). However, in order to 
study CaMKIIG function in the pathogenesis of atherosclerosis, this model had to be 
introduced into an ApoE-/- background. Therefore, the second aim of this PhD was to develop 
and characterise atherosclerosis in the double knockout (dKO) (ApoE-/-CaMKIIG-/-) mouse.  
 
3.2.1 Animal work 
 
CaMKIIG-/- mice were generated as previously described [240] by the Joan Heller-Brown lab 
and donated for the following experiment. Initially, ApoE-/-CaMKIIG+/+ and ApoE+/+CaMKIIG-/- 
mice were bred to give rise to a litter heterozygous for ApoE and CaMKIIG (F2). Following this, 
breeding pairs of mice with an ApoE-/-CaMKIIG+/- genotype were selected for and bred as the 
F3 generation (Figure 3.1). Tail tips from the litters of the F3 breeding pairs were used for RT-
PCR to confirm genotype. Twelve  ApoE-/- CaMKIIG+/+ (control) and ApoE-/-CaMKIIG-/-  (dKO) 
male and female mice (total n = 48) were housed until 20-week of age at the Hercus Taieri 
Research Unit (HTRU), under a 12:12 hr lighting schedule with ad libitum access to food and 
water. Twelve male and female mice per group were selected for the sample size as this is the 
number previously used in our lab to determine significant differences. This experiment was 




Figure 3.1: Summary of breeding generations to develop the ApoE-/-CaMKIIG-/-. 
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3.2.1.1 DNA extraction and genotyping 
 
The tail tips from litters of ApoE-/-CaMKIIG+/- (heterozygous) mice were put in a 
microcentrifuge tube with 200 µL DNA extraction buffer (100 mM Tris, 5 mM EDTA, 200 mM 
NaCl, 0.2% SDS, 100 µg/ml proteinase K, pH 8.5). The tubes were incubated at 55°C for 2 hr 
and then 98°C for 15 min. The samples were stored at 4°C until RT-PCR. 
 
0.5 µL of DNA extract from tail tips was used for RT-PCR using the KAPA HiFi HotStart 
ReadyMix. The reaction components are described in Table 3.1. A list of primers used for ApoE-
/-, CaMKIIG wild-type (wt) and KO genes are provided in Table 3.2. PCR amplification was 
performed in a thermal supercycler (Kyratec). A no template control (NTC) was performed for 
each RT-PCR experiment, where the DNA sample from the tip is replaced with ready mix. This 
was to control for any contaminant DNA that might be present in the other components of 
the PCR reaction mix. 
 
 
Table 3.1 PCR mastermix reaction. 
 
Reagent Volume/reaction (µL) 
KAPA HiFi HotStart ReadyMix (KAPA 
Biosystems, cat.no. KRO370) 
12.5 
Forward primer 0.75 
Reverse primer 0.75 





Table 3.2 Primer sequences and cycling conditions for genotyping. 
 
Primer Sequence Cycling  
 
Target Size 
ApoE   
 
180 5’-GCCTAGCCGAGGGAGAGCCG-3’ 98°C (10 sec) 
68°C (15 sec) 




180 & 181 = 155 bp 
Mutant allele 







F 5’-GGAGCATTTCATCTGTAGGTG-3’ 98°C (10 sec) 
62°C (20 sec) 









96°C (20 sec) 
70°C (20 sec) 
68°C (20 sec) 







Following RT-PCR, reaction products were mixed with BlueJuice Gel Loading Buffer (10X) 
(ThermoFisher, cat.no. S33102) and run alongside the NTC on 1.5% agarose gels for 60 min, 
as previously described in Section 2.2.3. The size of each amplified product was confirmed by 
comparing with a 100 kb DNA marker (Thermofisher, cat.no. 15628050) that was 
electrophoresed in parallel with samples. Agarose gels were placed in the PXi 4 Touch Multi-
Application Gel Imaging System (Syngene, PXi 4 Touch) and images digitally captured. 
 
3.2.1.2 Dissection of the aortic sinus 
 
At 20-weeks of age ApoE-/- (control) and ApoE-/-CaMKIIG-/- (double knock-out (dKO)) mice were 
euthanised by carbon dioxide (CO2) overdose and death was confirmed by pedal withdrawal 
reflex. The mouse was weighed and set on a dissection board with chest and stomach 
exposed. Each mouse was then perfused with 30 mL heparinised PBS (40 U/mL) via the apex 
of the heart, as previously described in Section 3.2.2. The perfusion solution was then changed 
to 4% paraformaldehyde (PFA) and the aortic tree was perfused for a further 10 min. 
 
To isolate the aortic sinus, the heart was cut in a transverse plane below the level of the left 
and right atria. The heart was then trimmed around the ventricular outflow tract and atria to 
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identify the aortic sinus (Figure 3.2). The aortic sinus was returned to 4% PFA for 48 hr for 






Figure 3.2: Anatomy of the aortic sinus. Mice were perfusion fixed with 4% PFA and the heart dissected. 
The heart was cut in a transverse plane below the level of the atria and trimmed to isolate the aortic 
sinus. Views of the aortic sinus from a superior and inferior aspect (A-B). The red ring highlights the 
aortic sinus which is zoomed in on C-D indicating the closed and open position of valve leaflets. Aortic 
sinus was cut longitudinally and pinned flat to observe the valve leaflets. 
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3.2.1.3 Total cholesterol ELISA 
 
To investigate total cholesterol levels in both control and dKO mouse groups, an ELISA was 
performed using the HDL and LDL/VLDL Cholesterol Assay Kit (Abcam, cat.no.65390). Firstly, 
a set of cholesterol standards were diluted to a total volume of 50 µL using cholesterol assay 
buffer. The standards ranged from 0 to 5 µg/50 µL by intervals of 1 µg. Secondly, 2 µL of serum 
was diluted 1:25 by mixing with 48 µL cholesterol assay buffer. 50 µL of standards and samples 
were added to a 98 well plate in triplicate. 50 µL of the reaction mix, described in Table 3.3, 
was added to standards and samples before being incubated at 37°C for 1 hr.   
 
Table 3.3 Cholesterol reaction mix. 
 
Component Total cholesterol reaction mix ( µL) 
Cholesterol assay buffer 4 
Cholesterol probe 2 
Enzyme mix 2 
Cholesterol esterase 2 
 
Post-incubation, the plate was removed from the incubator and output was measured on a 
microplate reader at optical density (OD) 570 nm. The mean absorbance (A570) value was 
calculated between triplicates for standards and samples.  Using GraphPad Prism 8, 
absorbance values for standards were plotted against concentration (Figure 3.3). A line of best 
fit (y = mx + c) was generated from the data points and used to calculate cholesterol in serum 
samples. The value was then multiplied by the initial dilution factor to calculate serum 













Figure 3.3: Example standard curve for total cholesterol. Six cholesterol standards were diluted 
ranging from a concentration of 0 to 5 µg in 50 µL assay buffer. The cholesterol standards were added 
to a 98-well plate in triplicate. 50 µL of the cholesterol reaction mix was added to each standard well 
and the plate was incubated at 37°C for 1 hr. Optical density (OD) was measured at 570 nm. Mean 
absorbance values were calculated and plotted against cholesterol using GraphPad Prism 8. A line of 





3.2.2.1 Tissue processing and embedding 
 
The aortic sinus was removed from 70% ethanol and placed in a histological cassette for tissue 
processing. This process dehydrates the tissue through a series of wash steps from ethanol to 
xylene and finally, paraffin wax, as shown in Table 3.4. 
 
Table 3.4 Short tissue processing cycle. 
Stage Solvent Time (min) 
1. 70% ethanol 15 
2. 900% ethanol 15 
3. 100% ethanol 105 
4. Xylene 85 
5. Paraffin wax 105 
 
Post-tissue processing, the cassettes were transferred to a tray of paraffin wax at 60°C for 1 
hr. This was to allow the wax to melt around the tissue so the aortic sinus could be 
manipulated for embedding. The aortic sinus was placed in a block tray flat against the 
transverse plane it was cut on during dissection. For further confirmation, the lumen of the 
ascending aorta was visible and pointed directly upwards. Each block mould was filled to the 
top with additional paraffin wax and placed on a cold plate for 1 hr to set. 
 
3.2.2.2 Tissue Sectioning 
 
The Paraffin blocks containing aortic sinus tissue were pre-cooled in the fridge to harden wax 
prior to sectioning. Each block was clamped into the microtome and the cutting dial adjusted 
to 20 µm. The block was trimmed until at least two valve leaflets of the aortic sinus were 
present in the section with the aid of a light microscope (Figure 3.4A). Once this region was 
located, the cutting dial was adjusted to 5 µm. A section was collected and transferred to 30% 
ethanol to reduce surface tension and prevent folding. The section was transferred to a 37°C 
water bath to melt surrounding wax. A microscope slide with a poly-lysine coat was used to 
collect and adhere the section and placed on a heating rack. Four more sections were collected 
at 100 µm intervals throughout the aortic sinus as shown in Figure 3.4. Slides containing 




Figure 3.4: Sectioning of the aortic sinus in a representative ApoE-/- mouse. The aortic sinus was cut 
along the longitudinal plane and pinned flat (X.). Indicated by the black trace is one of three valve 
leaflets. Red dotted lines provide each target location along the aortic sinus for sectioning. At the 
appearance of the first two valve leaflets a 5 µm section was collected (A.). Four more sections were 
collected at 100 µm intervals throughout the aortic sinus (B-E). Sections stained with Verhoeff van 
Gieson. Histology images taken with a light microscope.  
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3.2.2.3 Verhoeff van Gieson stain 
 
The Verhoeff van Gieson staining method is useful in identifying major components of the 
vascular wall [242]. In particular, this approach is useful in identifying elastin fibres, vascular 
smooth muscle cells and extracellular matrix (ECM). Prior to staining, each slide was 





Figure 3.5 Rehydration and dehydration of aortic sinus sections. Prior to staining, slides containing 
aortic sinus sections were run through a series of washes from xylene, through a reducing concentration 
of ethanol to water. Once sections were at this point they were stained with Verhoeff van Gieson stain. 




Components for the Verhoeff van Gieson staining method are described in Table 3.5. Slides 
were submerged in Verhoeff’s haematoxylin solution for 20 min to saturate the tissue section. 
The slide rack was then drained, washed under tap water and placed in distilled water. 
Individually, each slide was carefully submerged in 2% ferric chloride from 45-60 sec to strip 
the Verhoeff’s haematoxylin so the stain is only retained in the elastin fibres. The slides were 
washed in distilled water and rinsed in 95% alcohol. The slide rack was then dipped in Van 
Gieson solution for 30 sec. Slides were then dehydrated back to xylene, in the reverse order 
of rehydration method and cover-slipped (Figure 3.5). 
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Table 3.5 Components of the Verhoeff van Gieson staining method. 
 
Solution Components Volume (ml) 
Verhoeff’s haematoxylin 
working solution 
Alcoholic haematoxylin (5%) 125 
Ferric chloride (10%) 50 
Lugols iodine 50 
Van Gieson Saturated aqueous picric acid 500 
Acid fuschin (1%) 90 
Distilled water 500 
2% Ferric chloride Ferric chloride (10%) 100 
Distilled water 400 
 
 
3.2.2.4 Lesion area and volume analysis 
 
Lesion area was measured in five points along the aortic sinus of ApoE-/- and ApoE-/-CaMKIIG-/- 
as described in Section 3.2.2.2. This is an effective method of analysis as it provides detail on 
the distribution of lesion growth in the aortic sinus as well as total lesion content. 
 
Images were captured digitally using a Motic£ Microscope (BA130 Motic Inc. LTD) at 20X 
magnification so the whole aortic sinus was in the field of view. Digital images were analysed 
using Image J (imagej.nih.govt/ij/download/2016). Using the free hand trace tool, one area 
was drawn around the internal boundary of the internal elastic lamina (A) (stained black from 
VVG). A second area was then drawn within the lumen area (B). Foam cell lesion area was 
calculated by the difference in these two areas as shown in Equation 3.1.  
 
Equation 3 1: Calculating foam cell lesion area. 
Foam cell lesion area = A – B 
 
Foam cell lesion area measurements were calculated on GraphPad Prism 8 and expressed as 
mean r SEM for each group along each point (100 µM intervals) along the aortic sinus. The 
area under the curve was measured for each group to calculate foam cell lesion volume in the 




All data was analysed on Graphpad Prism 8 and expressed as mean r SEM. Significant 
differences were determined by Students unpaired t-test. For body weight and total 
cholesterol of the ApoE-/-CaMKII-/- significant differences were determined using a two-way 




3.3.1 Development of a new ApoE-/-CaMKIIG-/- mouse model.   
 
To identify the impact of CaMKIIG on the pathogenesis of atherosclerosis, ApoE-/- mice were 
crossed over a series of breeding pairs to generate the ApoE-/-CaMKIIG-/- mouse model as 
described in Section 3.2.1. DNA was extracted from the tail tips of each litter of the F3 breeding 
pairs and used in RT-PCR targeting ApoE, CaMKIIG wt allele and CaMKIIG mutant (KO) allele. 
Products of PCR were electrophoresed on a 1.5% agarose gel for an hour and digital images 
were captured using the Syngene PXi 4 touch. 
 
Shown in Figure 3.6, an example experiment confirming the genotypes of eight mice from a 
new litter. In gel A targeting ApoE, if the wt allele is present the primer pairs 180-181 yield 
product of 155 bp in the PCR reaction [241]. Furthermore, if the mutant allele (KO) is present 
primer pairs 180-182 yield a product size of 245 bp [241].  In the case of the CaMKIIG gene, 
the presence of wt  and mutant (KO) alleles is indicated by product sizes of 220 bp and 350 
bp, respectively [240]. 
 
After confirmation of genotype, ApoE-/-CaMKIIG+/+ (control) and ApoE-/-CaMKIIG-/- (dKO) mice 
were housed in HTRU until 20 weeks of age. What was evident in some of the litters with a 
dKO phenotype was the appearance of ataxic behaviour. This included head nodding and an 
inconsistent gait. These were only moderate signs of ataxia and did not significantly affect 











Figure 3.6: Genotyping experiment example.  DNA was extracted and RT-PCR was carried out 
targeting ApoE and CaMKIIG genes. Products of PCR were loaded onto a 1.5% agarose gel alongside a 
no template control (NTC) and electrophoresis applied at 100 V for 60 min. Digital images were 
captured using the Syngene PXi 4 touch. PCR products of 155 bp and 245 bp indicated the ApoE wt 
allele and the ApoE mutant (KO) allele (A). The presence of the CaMKII wt and KO alleles is indicated by 
product sizes of 220 bp and 350 bp, respectively (B-C).  100 bp DNA marker (Invitrogen, cat.no. 







To further validate this novel model for the upcoming experiments it was important to 
determine any differences in body weight and total cholesterol between control and dKO 
mice. Cholesterol is the major risk factor for atherosclerosis [14, 16] so it was important to 
identify whether knocking out CaMKIIG had any effect on lipid transport and metabolism. At 
20-weeks of age, male and female control and dKO mice were euthanised by CO2 overdose. 
Mice were weighed and a blood sample was collected via cardiac puncture. The serum was 
extracted from the blood and total cholesterol analysed by ELISA, as described in Section 
3.2.1.3.  
 
There were no differences shown in body weight between ApoE-/- (control) and ApoE-/-
CaMKIIG-/- (dKO) mice in both males (p = 0.17, n = 8), and females (p = 0.57, n = 8) (Figure 3.7). 
No differences were observed in total cholesterol between control and dKO mice in males (p 
= 0.98, n = 8) and females (p = 0.99, n = 0.99) (Figure 3.8). Furthermore, no differences were 
shown between male and female control mice (p = 0.64, n = 8), as well as any other 
comparison between groups.  
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Figure 3.7: Body weight at 20-weeks age in male and female ApoE-/- and CaMKIIG-/- mice. At 20-weeks 
age ApoE-/- (control) and ApoE-/-CaMKIIG-/- mice were euthanised and weighed. Weights were analysed 
on GraphPad Prism 8. Non-significant (N.S) as determined by two-way ANOVA with Tukey’s multiple 
comparisons post-hoc test (n = 8). 
 
Figure 3.8: Total cholesterol at 20-weeks age in male and female ApoE-/- and CaMKIIG-/- mice. At 20-
weeks age ApoE-/- (control) and ApoE-/-CaMKIIG-/- mice were euthanised and blood samples collected by 
cardiac puncture. Serum was extracted from blood and total cholesterol measured using the HDL and 
LDL/VLDL Cholesterol Assay Kit (Abcam, cat.no.65390) as detailed in Section 3.2.1.3. Total cholesterol 
values were analysed on GraphPad Prism 8. Non-significant as determined by two-way ANOVA with 
Tukey’s multiple comparisons post-hoc test (n = 8). 
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3.3.2 Genetic knockdown of CaMKIIG has no effect on aortic sinus lesion size in 
20-week male ApoE mice. 
 
What was immediately striking was the difference in atherosclerosis content between male 
and female groups. By examination under a light microscope it was clear that both female 
groups contained more atherosclerosis than counterpart male groups. In the male control and 
dKO groups, the aortic tree, which included the aortic arch, brachiocephalic artery, left carotid 
and left subclavian artery, was relatively translucent in appearance. In contrast, the aortic tree 
from female control and dKO groups contained large opaque regions, indicative of foam cell 
lesions. These lesions were primarily observed around bifurcating areas of the aortic tree. 
 
The aortic sinus of male control (ApoE-/-CaMKIIG+/+) and dKO (ApoE-/-CaMKIIG-/-) mice was 
sectioned and stained with VVG for lesion analysis (Section 3.2.2). Male control and double 
KO mice both displayed areas of intimal thickening and very small areas of foam cell lesion 
growth on the arterial wall within the aortic sinus valve leaflets (Figure 3.9-10). Furthermore, 
these early lesions were present at the base of the aortic sinus (0µm) and persisted through 
the aortic sinus trunk toward the aorta (400µm). After the area under the curve was 
calculated, there were no significant differences in aortic sinus lesion volume in double KO (90 
r 13 µm3) vs control mice (126 r 30 µm3)  (p = 0.20, Students unpaired T-test, n = 9 ApoE-/-
CaMKIIG+/+, 11 ApoE-/-CaMKIIG-/-) (Figure 3.11). This indicates that in males atherosclerosis is 




Figure 3.9: Foam cell lesions in the aortic sinus of 20-week male control (ApoE-/-CaMKII+/+) mice. Male 
control mice were housed until 20 weeks of age. Mice were perfusion fixed with 4% PFA and the heart 
dissected. The heart was cut in a transverse plane below the level of the atria and embedded in paraffin 
wax.  Shown above is a representative aortic sinus from a 20-week control male. A 5 µm section was 
collected at the appearance of the first two valve leaflets (A) and 4 more collected at 100 µm intervals 
throughout the aortic sinus (B-E). Each section was stained with Verhoeff van Gieson and photos 
captured with a light microscope. The red boxes indicated by black and red asterisks correlate to 
zoomed in image of the vessel wall shown in F-G. Yellow double arrow indicated foam cell lesion growth 




Figure 3.10: Foam cell lesions in the aortic sinus of 20-week male dKO (ApoE-/-CaMKII-/-) mice. Male 
dKO mice were housed until 20 weeks of age. Mice were perfusion fixed with 4% PFA and the heart 
dissected. The heart was cut in a transverse plane below the level of the atria and embedded in paraffin 
wax.  Shown above is a representative aortic sinus from a 20-week dKO male. A 5 µm section was 
collected at the appearance of the first two valve leaflets (A) and 4 more collected at 100 µm intervals 
throughout the aortic sinus (B-E). Each section was stained with Verhoeff van Gieson and photos 
captured with a light microscope. The red boxes indicated by black and red asterisks correlate to 
zoomed in image of the vessel wall shown in F-G. Yellow double arrow indicated foam cell lesion growth 




Figure 3.11: Foam cell lesion quantification in the aortic sinus of 20-week male control (ApoE-/-
CaMKII+/+) and dKO (ApoE-/-CaMKII-/-) mice. A section was collected every 100 µm throughout the 
aortic sinus of each mouse and stained with Verhoeff van Gieson. Lesion area was calculated for each 
section along the aortic sinus (A). The area under the curve was calculated to generate foam cell lesion 
volume (B). Graphs show mean foam cell lesion area/volume as mean r S.E.M. Not significant (N.S) as 
determined by unpaired Students t-test (n = 9-11).  
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 3.3.3 Genetic knockdown of CaMKIIG reduces aortic sinus lesion size in 20-
week female ApoE mice. 
 
Genetic knockdown of CaMKIIG had no significant effect on lesion size in the aortic sinus of 
male ApoE mice. However, it is known that on the C57/Bl6 background that male lesions 
progress slowly and in both control and dKO groups, there were only small pockets of foam 
lesion growth. It was next investigated whether CaMKIIG promotes foam cell lesion growth in 
the aortic sinus of female ApoE-/- mice using the same approach described for males. The aortic 
sinus of female control (ApoE-/-CaMKIIG+/+)  and dKO (ApoE-/-CaMKIIG-/-) mice was sectioned 
and stained for lesion analysis.  
 
As expected for this model, female mice showed more atherosclerosis at 20-weeks of age 
compared to males. In the control (ApoE-/-CaMKIIG+/+) group, some mice presented with large 
foam cell lesions that extended the length of each valve leaflet and was also present 
throughout the whole trunk of the aortic sinus (Figure 3.12). The dKO (ApoE-/-CaMKIIG-/-) mice 
had lesions present throughout the trunk of the aortic sinus however they were sporadic and 
did not extend the full length of the valve leaflets (Figure 3.13). Foam cell lesion volume in 
control and dKO groups was 357 r 55 µm3 and 195 r 24 µm3, respectively (Figure 3.14). When 
compared, there was a significant decrease in lesion content in dKO group of 162 µm3 (P<0.05, 





Figure 3.12: Foam cell lesions in the aortic sinus of 20-week female control (ApoE-/-CaMKII+/+) mice. 
Female control mice were housed until 20 weeks of age. Mice were perfusion fixed with 4% PFA and 
the heart dissected. The heart was cut in a transverse plane below the level of the atria and embedded 
in paraffin wax.  Shown above is a representative aortic sinus from a 20-week control female. A 5 µm 
section was collected at the appearance of the first two valve leaflets (A) and 4 more collected at 100 
µm intervals throughout the aortic sinus (B-E). Each section was stained with Verhoeff van Gieson and 
photos captured with a light microscope. The red boxes indicated by black and red asterisks correlate 
to zoomed in image of the vessel wall shown in F-G. Yellow double arrow indicated foam cell lesion 





Figure 3.13: Foam cell lesions in the aortic sinus of 20-week female dKO (ApoE-/-CaMKII-/-) mice. 
Female dKO mice were housed until 20 weeks of age. Mice were perfusion fixed with 4% PFA and the 
heart dissected. The heart was cut in a transverse plane below the level of the atria and embedded in 
paraffin wax.  Shown above is a representative aortic sinus from a 20-week dKO female. A 5 µm section 
was collected at the appearance of the first two valve leaflets (A) and 4 more collected at 100 µm 
intervals throughout the aortic sinus (B-E). Each section was stained with Verhoeff van Gieson and 
photos captured with a light microscope. The red boxes indicated by black and red asterisks correlate 
to zoomed in image of the vessel wall shown in F-G. Yellow double arrow indicated foam cell lesion 






Figure 3.14: Foam cell lesion quantification in the aortic sinus of 20-week female control (ApoE-/-
CaMKII+/+) and dKO (ApoE-/-CaMKII-/-) mice. A section was collected every 100 µm throughout the aortic 
sinus of each mouse and stained with Verhoeff van Gieson. Lesion area was calculated for each section 
along the aortic sinus (A). The area under the curve was calculated to generate foam cell lesion volume 
(B). Graphs show mean foam cell lesion area/volume as mean r S.E.M.. *P < 0.05 as determined by 
unpaired Students t-test (n = 9-11).  
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In summary, knocking the CaMKIIG gene from our atherosclerotic mouse model (ApoE-/-) did 
not have comparable effects on lesion size between males and females. At 20 weeks there 
was little atherosclerosis present in the aortic sinus of male groups and no difference observed 
between control and dKO. In contrast female groups had extensive lesions along the valve 
leaflet vessel wall of the aortic sinus. Interestingly, the dKO group had a striking reduction in 
lesion volume in the aortic sinus compared to control. Whether or not any male effect is 
masked due to lack of disease progression could indeed be a factor. Collectively, the strong 
effect observed in females where atherosclerosis is more advanced suggests the CaMKIIG 





In this investigation, a genetic approach was employed by crossing ApoE-/- mice 
(atherosclerosis model) with CaMKIIG-/- mice to generate a novel model  ApoE-/-CaMKIIG-/- 
(dKO). Using this model it was identified the contribution of CaMKIIG to atherosclerosis. 
Histological analysis of atherosclerosis in the aortic sinus of male and female control (ApoE-/-
CaMKIIG+/+) and dKO (ApoE-/-CaMKIIG-/-) groups suggests CaMKIIG plays a role in foam cell 
lesion development.   
 
What was striking was the dramatic differences in atherosclerosis between males and 
females. During dissection, it was noticeable that the aortic tree of male mice was translucent 
in appearance. In contrast, the aortic tree of female mice was opaque indicative of foam cell 
lesion build up within the artery wall. An extensive analysis of foam cell lesion content in the 
aortic sinus of males revealed there was little atherosclerosis present and no differences 
observed between control and dKO groups (Figure 3.9-11). As our measurement was foam 
cell lesion area, many of the males did not present with extensive foam cell lesions so it was 
difficult to measure differences. 
 
In the female groups however, there was extensive atherosclerosis development. This 
included extensive foam cell lesions that were present in the valve leaflets of the aortic sinus 
and extended the through the trunk of the aortic sinus (0 µm – 400 µM) (Figure 3.12-14). 
When groups were quantified there was roughly three times more lesion content in combined 
female control and dKO groups compared to male counterpart groups. 
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The finding that there is more atherosclerosis present in the aortic sinus of female mice at 20-
weeks is not novel. Males are more resistant to the development of atherosclerosis and 
different effects are seen between sex when ApoE-/- mice are bred over different genetic 
backgrounds [236-238]. This includes the C57/Bl6 strain, which was the background strain for 
the current experiments [239]. Regardless of differences in disease progression we were 
interested in the role CaMKIIG played in the development of atherosclerosis. 
 
Female dKO mice had significantly less foam cell lesion in the aortic sinus compared to female 
control mice (Figure 3.14). Both groups had lesions present that extended the length of the 
aortic sinus however the lesions from control group were more progressed. Measuring lesion 
content in female groups was easy due to the large continuous lesions present. In contrast the 
small pockets of lesions present in male groups were more challenging to measure. It is likely 
that lack of disease progression is masking any effect of CaMKIIG. In future, it would be useful 
to age mice until they reach a stage of lesion progression seen in the female counterpart group 
at 20-weeks and identify any differences at this time point. Regardless of the results shown by 
male, the strong effect seen between female groups suggest CaMKIIG is a key player in foam 
cell lesion development. 
 
As we were establishing a novel mouse model it was important body weight and total 
cholesterol was measured between male and female control and dKO mice. Total cholesterol 
is a risk factor for the development of atherosclerosis so it was important to identify whether 
knocking out the CaMKIIG had any effects on cholesterol metabolism/ transport. Body weight 
and total cholesterol was not different between control and dKO groups in males and female 
(Figure 3.7-8). As cholesterol levels were not different it was not required to investigate the 
serum lipid profile in more depth by looking at HDL and LDL-C/VLDL-C. This suggests that 
CaMKIIG is not playing a role in atherosclerosis by altering cholesterol metabolism. 
 
Previously, we showed global inhibition of CaMKII with KN-93 reduced foam cell lesion 
development. This new model is advantageous over the former as it is selectively blocking 
CaMKIIG expression while preserving  the expression and physiological actions of the other 
isoforms. A limitation of the model in the context of the whole PhD is that we are interested 
in splice variants of the CaMKIIG isoform. This is because there is evidence for splice variant-
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specific functions. If it was investigated what splice variant of CaMKIIG is contributing to 
atherosclerosis we would have to design specific siRNAs against the different variants.  
 
Interestingly, some of the dKO mice from breeding litters displayed an ataxic phenotype. This 
neurological behaviour was unexpected as CaMKIID and E are the main neural isoforms so it 
was expected any brain function would be preserved when knocking out CaMKIIG. Even 
though CaMKIID and E are the predominant cardiovascular isoform there has been some 
expression of G found, however it has not been linked to any main function yet. This ataxic 
behaviour could be linked to any of the splice variants of CaMKIIG that may be present in the 
brain. This adverse phenotype is not desirable in the context of drug discovery, suggesting a 
more targeted approach is required.  
 
In summary, this is the first study to develop an atherosclerotic mouse model with a deletion 
in the CaMKIIG gene. Collectively, results obtained from the aortic sinus of control and dKO 
mice suggest CaMKIIG plays a role in foam cell lesion growth. Importantly, there were ataxia 
issues in some of the dKO mice suggesting one of the CaMKIIG variants may be playing a 
physiological role in the brain. For a more targeted investigation next, we need to over express 
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4.2.1 Cloning CaMKII into pAAV-mCherry 
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4.3.1 Validation of CaMKIIG2-/control-mCherry AAV particles in vitro. 
 
4.3.2 Ligation of the left carotid artery of ApoE-/-CaMKIIG-/- mice causes gross 
morphological  changes to the vascular wall. 
 
4.3.2 Ligation of the left carotid artery in ApoE-/-CaMKIIG-/- mice rapidly 
promotes foam cell lesion development and arterial wall remodeling wall. 
 
4.3.4. Detection of mCherry fluorescence in the carotid arteries of ApoE-/-
CaMKIIG-/- mice transduced with CaMKIIG2- and control-mCherry.  
 
4.3.5. CaMKIIG2 has no effect on vessel wall hypertrophy in response to ligation 
of the left carotid artery in ApoE-/-CaMKIIG-/- mice. 
 
4.3.6. Examining the effect of CaMKIIG2 on foam cell lesion growth in an 
accelerated model of atherosclerosis. 
 
4.3.7. Evaluating stenosis in the ligated carotid arteries of ApoE-/-CaMKIIG-/- 
mice transduced with CaMKIIG2- and control-mCherry.  
 
 




Atherosclerosis is a multifactorial disease characterised by the formation of foam cell lesions 
on the inner layer of the arterial wall [13]. The development of foam cell lesions in the 
coronary arteries and aortic tree are responsible for ischaemic attacks including myocardial 
infarction (MI) and stroke [23, 243]. Current therapies targeted towards reducing 
atherosclerosis include the use of statins. Statins have been successful at reducing cardiac 
event mortality and morbidity [113, 124, 125, 127], however, even when target LDL-C levels 
are met, there remains a residual risk for a cardiovascular event [224]. It is critical that 
alternative treatments are developed that can be used alongside statins to target 
atherosclerosis. Such treatments could be those that target cellular mechanisms which 
promote lesion growth.  
 
In vascular smooth muscle cells (VSMCs) and endothelial cells (ECs), calcium/calmodulin-
dependent protein kinase II (CaMKII) has emerged as a critical regulator of cellular function in 
health and disease [244, 245]. The predominant isoforms expressed in vascular cells are 
CaMKIIG and J (Chapter 2) [185, 197, 198]. The differentiation between each isoform is critical 
as the G and  J isoforms have shown contrasting roles in vascular function. In particular, G 
promotes cellular functions that drive vascular pathology, whereas, J has been shown to 
promote vascular health [213, 219, 221, 246].  
 
The G and J isoforms exist as  a number of splice variants, G1-11, J1-3 [197, 199, 200, 203]. These 
variants have only been identified in cells but, of interest, the G2 and G6 have been investigated 
in relation to variant specific function. CaMKIIG2 has been shown to promote VSMC 
proliferation and migration [219, 220]. In contrast, CaMKIIG6 has been associated with 
thrombin-induced increase in endothelial cell permeability and expression of vascular cell 
adhesion molecules (e.g. VCAM-1) [212, 218]. Collectively, these functions in VSMCs and ECs 
are mechanisms that contribute to foam cell lesion development.  
 
CaMKII function is yet to be investigated in a model of atherosclerosis (ApoE-/-). Some of the 
previous research in CaMKII employed AAV-mediated techniques, and these approaches have 
been effective at unravelling some of the functions of CaMKII in pathology [181, 213, 247]. 
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Already, it has been shown that CaMKIIG promotes lesion development in the aortic sinus of 
ApoE-/- mice using a genetic knockout model (ApoE-/-CaMKIIG-/-) (Chapter 3). To provide 
unequivocal evidence of CaMKIIG involvement, it is now important to over-express the G 
isoform using an AAV-mediated approach to fully exemplify CaMKIIG contribution to foam cell 







So far, the results gathered suggest CaMKIIG plays a role in atherosclerosis. In Chapter 3, it was 
shown that female ApoE-/-CaMKIIG-/- had a strikingly reduced foam cell lesion content in the 
aortic sinus at 20-weeks of age compared to control females (ApoE-/-CaMKIIG+/+). In both male 
ApoE-/-CaMKIIG-/- (dKO) and ApoE-/-CaMKIIG+/+ (control) groups, there was minimal 
atherosclerosis in the aortic sinus so the disease was not progressed enough to measure any 
difference.  
 
To provide further mechanistic evidence that CaMKIIG promotes foam cell lesion 
development, an over-expression approach was employed. More specifically, AAV particles 
encoding either CaMKIIG2 or a scrambled sequence (control) were grown as detailed in Section 
4.2.1-2. The CaMKIIG2 variant was chosen for two main reasons. Firstly, from the limited 
literature that has focused on a specific variant, CaMKIIG2 is described as causing cellular 
pathology including VSMC proliferation and EC dysfunction [212, 218-220]. Secondly, in 
Chapter 2, the G2 was shown to be present in human vascular cells as well as the 
atherosclerotic arteries of ApoE-/- mice.  
 
ApoE-/-CaMKIIG+/- mice were mated and offspring litters were genotyped as described in 
Section 3.2.1.1. At 16-weeks of age,  the carotid artery of ApoE-/-CaMKIIG-/- mice was ligated 
to disturb blood flow and accelerate atherosclerosis [248-251]. AAV particles harbouring 
either CaMKIIG2- or control-mCherry were then introduced into the tissue of the ligated artery. 
After surgery and recovery, the mice were returned to housing until mice were 20-weeks of 
age. At this time, mice were euthanised and perfused-fixed as previously described (WHERE). 
Both the left ligated carotid and right non-ligated carotid artery were dissected and processed 
through histology. The carotid arteries of CaMKIIG2 and control groups were analysed for foam 








4.2.1 Cloning CaMKII into pAAV-mCherry  
 
To develop a CaMKII expressing AAV particle, initially, two plasmids containing the CaMKIIG2 
and CaMKIIJ3 open reading frames (ORFs) were purchased from GenScript The CaMKIIG2 
sequence was selected as it is a predominant splice variant in the vasculature of humans and 
a mouse model of atherosclerosis (ApoE-/-) as previously discussed (where). While the G 
isoform is the primary target for investigation, an additional variant of the “protective” J3  
sequence was cloned and developed into a virus, to act as a method control and to be used in 
an independent parallel experiment.   
 
The backbone plasmid (pAAV-hSyn-hM4D(Gi)-mCherry (Addgene)) was digested and the 
CaMKII sequences amplified by PCR. Amplified CaMKII inserts were ligated into the virus 





Figure 4.1: Summary of CaMKIIG2 and J3 cloning procedure. CaMKIIG2 and J3 ORFs were purchased as 
pcDNA3.1+C-(K)-DYK vectors (A-B) and amplified via PCR. The pAAV-hSyn-hM4D(Gi)-mCherry backbone 
plasmid (GenScript) (C) was digested utilising restriction sites MluI (139) and AgeI (2105). Amplified 
CaMKIIG2 and J3 ORFs were ligated into the digested backbone resulting in pAAV-CaMKIIG2/J3-mCherry 






4.2.1.1 Digest of AAV-backbone vector 
 
The pAAV-hSyn-hM4D(Gi)-mCherry plasmid (Genscript) was used as the virus backbone (Fig. 
4.2). The plasmid was digested by utilising restriction enzyme sites MluI (139) and AgeI (2105) 




Figure 4.2: Basic structure of pAAV-hSyn-hM4D(Gi)-mCherry. The 6726 bp plasmid encodes the hSyn 
promoter, mCherry reporter gene, ampicillin resistance gene and inverted terminal repeat sequence 
(ITR). MluI (139) and AgeI (2105) are restriction enzymes which flank a 1966 bp segment. 
 
 
Firstly, 12 µL (2 µg) of pAAV-hSyn-hM4D(Gi)-mCherry was mixed with 5 µL cut-smart buffer 
(10X) and 29 µL DEPC treated water in a 1.5 ml microcentrifuge tube. 2 µL of each restriction 
enzyme; MluI (cata.no. R31985) and AgeI-HF (cata.no. R35525), were added to the buffer mix 
and incubated for 15 mins at 37°C. Following this, the reaction was inactivated by heating to 
65°C for 5 mins. Figure 4.3 shows the plasmid digest products electrophoresed through a 1% 
agarose gel. The plasmid treated with restriction enzymes MluI/AgeI contains two bands 
which indicate the cut-out insert (1966 bp) and the rest of the plasmid (4760 bp). The top DNA 
fragment containing the backbone of the plasmid without the insert was excised from the gel 











Figure 4.3: pAAV-hSyn-hM4D(Gi)-mCherry digest. 1 µg of pAAV-hSyn-hM4D(Gi)-mCherry plasmid, 
either non-treated or digested with MluI and AgeI, was loaded into a 1% agarose gel containing SYBR 




4.2.1.2 Amplification of CaMKII Open Reading Frames (ORFs) 
 
The CaMKIIG2 and J sequences were purchased as the pcDNA3.1+C-(K)-DYK vectors (Genscript) 
(Fig. 4.4). Plasmid vectors containing CaMKII insert sequences were reconstituted in 100 µL 





Figure 4.4: Basic structure of pcDNA3.1+C-(K)-DYK. The CaMKIIG2 (A) and J3 (B) ORFs were encoded 
within each plasmid. Other features of the plasmid include the ampicillin resistance gene and restriction 
enzyme site MluI (228) upstream of CMV promoter and CaMKIIG2/J3 ORF.  
 
 
PCR was carried out to amplify CaMKIIG2 and J3 ORFs including the CMV promoter. The 
forward primer (MluI-CMV-fwd: 5’GATATACGCGTTGACATTGATTATTGAC-3’) is the same for 
both G2 and J3 sequences, utilising the MluI restriction enzyme site upstream of the CMV 
promoter in the pcDNA3.1+C-(K)-DYK vector. The AgeI restriction enzyme site was added for 
both the G2 and J3 reverse primer (AgeI-OMu23478D-CaMKIIG2-Rev: 5’-
GTATACCGGTAATCGATGTTTTGCCAC-3’ and AgeI-OMu16419D-CaMKIIJ3-Rev: 5’-
GTATACCGGTAATCCTGTAGCGGTGC-3’). This was to allow ligation of amplified G2 and J3 PCR 




For each PCR reaction, 12.5 µL KAPA HiFi mastermix (cat.no. KRO370) was mixed with 10 µL 
DEPC-treated water and 1 µL (2 ng) of pcDNA3.1+C-(K)-DYK vector. 0.75 µL of each respective 
forward and reverse primer for G2 and J3 was added to the mastermix and PCR performed 
under conditions shown in Table 4.1.  
 
Table 4.1: PCR conditions for CaMKIIG2 and J3 amplification from pcDNA3.1+C-(K)-DYK vector 
 
 98°C – 30 sec - 
Denaturing 98°C – 10 sec  
X 35 cycles Annealing 63°C – 20 sec 
Elongation 72°C – 60 sec 
 72°C – 5 min - 
 
 
Once PCR cycling had terminated, the PCR products were loaded into a 1% agarose gel and 
electrophoresed at 90 V for 1 hr. Figure 4.5 shows the amplified CaMKIIG2 and J3 products 
indicated by the white bands at sizes 2214 bp and 2207 bp, respectively. The amplified DNA 




Figure 4.5: PCR amplification of CaMKIIG2 and J3 ORFs in pcDNA3.1+C-(K)-DYK vector. PCR targeting 
CaMKIIG2 and J3 ORFs was carried out in duplicate. The total PCR product for each reaction was loaded 
into a 1% agarose gel (with SYBR safe DNA stain) alongside negative controls (-ve) and run at 90V for 
60 mins. Photo captured on Syngene imager. 
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4.2.1.3 DNA gel extraction, digestion and purification of CaMKII 
 
The DNA fragments from the digested backbone vector and amplified CaMKII ORFs were 
extracted from the gel using the QIAquick Gel Extraction Kit (cata.no. 29704 – Qiagen). Each 
gel fragment was weighed and incubated in 3X the gel volume of buffer QG at 50°C for 10 
mins. Following incubation, 1X gel volume of isopropanol was added to buffer and transferred 
to a spin column. The samples were centrifuged at 12000 x g and flow through was discarded. 
750 µL of wash buffer PE was added to each column and centrifuged at 12000 x g for 1 min or 
until all residual buffer had flowed through. Each column was eluted into a sterile 1.5 ml 
microcentrifuge tube. 40 µL of DEPC-treated water was added to each column and centrifuged 
at 12000 x g for 1 min. DNA concentrations were calculated using the Nanodrop. 
 
Once the CaMKIIG2 and J3 PCR fragments were extracted from the gel, they were digested 
using the MluI and AgeI restriction sites to allow ligation into the pAAV-hSyn-hM4D(Gi)-
mCherry plasmid. 5 µL of cut-smart buffer was mixed with 1 µL AgeI and MluI restriction 
enzymes. 2 µg of CaMKIIG2 or J3 PCR product was added to the buffer and adjusted with DEPC-
treated water to a final volume of 50 µL. Each sample was incubated for 15 min at 37°C. 
 
Following digestion, the CaMKIIG2 and J3 DNA fragments were purified using the QIAquick PCR 
kit (cata.no. 28104 - Qiagen). 250 µL of buffer PB (Qiagen) was added to 50 µL PCR digest 
product and mixed. The resulting sample was transferred to a column for DNA binding and 
centrifuged at 15,000 x g for 30 sec. The flow-through was discarded and the column washed 
with 750 µL buffer PE (Qiagen) and centrifuged in the same manner. The column was applied 
to a fresh microcentrifuge tube and 35 µL DEPC-treated water was added and centrifuged for 
1 min at 15,000 x g to elute DNA. DNA concentrations were calculated using the Nanodrop.  
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4.2.1.4 Plasmid Ligation 
 
Prior to plasmid ligation, the digested backbone pAAV-hSyn-hM4D(Gi)-mCherry was treated 
with recombinant shrimp alkaline phosphatase (rSAP). This was to prevent self-ligation of the 
digested plasmid. 2 µL of cut-smart buffer was incorporated with 0.25 µL rSAP and 200 ng of 
digested pAAV-hSyn-hM4D(Gi)-mCherry up to a volume of 20 µL. The sample was incubated 
for 30 min at 37°C and then heat inactivated for 5 min at 65°C. 
 
To set up ligation reaction, 30 ng of digested and rSAP-treated vector backbone was mixed 
with 5 µL of T4 ligase and 90 ng PCR digest (CaMKIIG2 or J3). The reaction was incubated for 15 
mins at room temperature and then overnight at 4°C. A simplified map of the ligated pAAV-





Figure 4.6: Structure of the developed pAAV-CaMKIIG2/J3-mCherry plasmid. The 6726 bp plasmid 
encodes the hSyn promoter, mCherry reporter gene, ampicillin resistance gene and inverted terminal 
repeat sequence (ITR). MluI (139) and AgeI (2105) are restriction enzymes which flank a 1966 bp 
segment. Original figure made on Microsoft PowerPoint. 
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4.2.1.5 Plasmid Transformation 
 
The One Shot Top10 competent E. coli (cata.no. C4040-10) were used to transform the newly 
ligated pAAV-CaMKIIG2/J3-mCherry plasmids. A 50 µL vial of One-Shot cells for each 
transformation was thawed on ice. 5 µL of each ligation reaction was added to a vial of cells, 
mixed gently and incubated on ice for 30 mins. Following this, each vial was transferred to a 
water bath for exactly 30 secs before being returned to ice. 250 µL of pre-warmed S.O.C (super 
optimal broth with catabolite repression, Thermofisher) media was added to each vial before 
shaking at 225 rpm for 1 hr at 37°C. 50 µL from each transformation vial was inoculated onto 
separate LB agar plates (100 µg/ml ampicillin). The plates were inverted and incubated 
overnight at 37°C. 
 
The following day the plates were observed for colony growth. Two new LB agar plates (100 
µg/ml Amp) were divided into seven segments. Seven separate colonies were swabbed from 
each of the pAAV-CaMKIIG2/J3-mCherry plates and streaked onto the fresh segmented plates. 
Additionally, each colony was run for PCR in the same manner as was used to amplify the 
CaMKIIG2/J3 ORFs from the pcDNA3.1+C-(K)-DYK vectors. Figure 4.7 shows the amplified 
CaMKIIG2 and J3 ORF indicated by the white bands at sizes 2214 bp and 2207 bp, respectively. 













Figure 4.7: PCR of CaMKIIG2 and J3 ORFs after ligation into pAAV-hSyn-hM4D(Gi)-mCherry. E. coli 
were grown and transformed overnight with either pAAV-CaMKIIG2-mCherry (A), or pAAV-CaMKIIJ3-
mCherry (B). Seven separate colonies from each transformation were swabbed and run for PCR 
targeting CaMKIIG2 (OMu23478) or CaMKIIJ3 (OMu16419). Total PCR products were loaded onto a 1% 




4.2.1.6 Plasmid midi prep 
 
After confirming the colonies were successfully transformed with pAAV-CaMKIIG2/J3-mCherry, 
a midiprep was carried out. Using a plastic loop, 100 ml LB media containing ampicillin (100 
µg/ml) was inoculated with either the pAAV-CaMKIIG2-mCherry, pAAV-CaMKIIJ3-mCherry, DJ 
or helper plasmids (catalog.no.VPK-400-DJ). The DJ and P-helper plasmids are co-transfected 
with pAAV-CaMKIIG2-mCherry to facilitate AAV production. Additionally, these plasmid 
constructs contain the ampicillin resistance gene so only bacteria successfully transformed are 
expected to grow. Flask cultures were put onto a shaker at 225 RPM overnight at 37°C.  
 
The PurelinkTM HiPure Plasmid DNA Purification Kit (Catalog.no. K2100-2) was used for plasmid 
extraction and purification. The following day, each flask was transferred to two 50 ml conical 
tubes and spun down at 4000 x g for 40 mins at 4°C. The supernatant was discarded and 4 ml 
resuspension buffer with RNase A was added to the cell pellet and mixed until homogenous. 
Following this, 4 ml lysis buffer was incorporated into the cell suspension and gently inverted 
before incubation at room temperature for 5 mins. After incubation, 4 mL of precipitation 
buffer was added and immediately mixed by inversion. The cell lysate was centrifuged at 
12,000 x g for 10 min. 
 
Following centrifugation, the supernatant fraction from the prepared cell lysate was loaded 
onto an equilibrated column. Once this had drained, 20 ml of wash buffer was run through 
the column to wash the bound DNA. A fresh 15 ml centrifuge tube was placed under the 
column and 5ml of elution buffer was added to the column to elute the DNA. 3.5 ml 
isopropanol was mixed thoroughly with elution tube and centrifuged at 12000 x g for 5 min at 
4°C. The supernatant was discarded, the DNA pellet resuspended in 3 ml 70% ethanol and 
centrifuged at 12000 G for 10 mins. The supernatant was carefully removed and the DNA 
pellet air dried for 10 mins. 100 µL DEPC-treated water was added to the pellet and left 
overnight at 4°C. A sample from each plasmid midi prep was run on a 1% agarose gel to identify 
plasmid size (Figure 4.8). The following day, the DNA concentration of cloned plasmids from 











Figure 4.8: Confirmation of plasmid midi prep. A midi prep for pAAV-CaMKIIG2-mCherry, pAAV-
CaMKIIJ3-mCherry, DJ or helper plasmid was carried out. A 3 µL sample of each plasmid was loaded 
into a 0.5% agarose gel (SYBR safe DNA stain) and electrophoresed at 70 V for 2 hrs. Photo captured 




4.2.2 Cell Culture 
 
4.2.2.1 Transfection of 293 AAV cells 
 
To generate the CaMKIIG2- and J3-expressing particles, 293AAV cells were used (Cat.no. AAV-
100 CELLBIOLABS). The 293AAV cell line are terminally differentiated, originating from primary 
embryonic human kidney transformed with adenovirus type 5 DNA. The transformed DNA 
encodes genes important for transactivation of viral promoters to drive replication. To achieve 
a high titre of virus the AAV-DJ Helper Free Packaging System (Cata.no. VPK-400-DJ 
CELLBIOLABS) was used. This kit provides two plasmids, pHelper and DJ, which assist 293AAV 
cells with the other required proteins for effective viral gene production and packaging. 
 
To mediate transfection, the Lipofectamine 3000 kit was used. Alongside CaMKII transfections 
an additional control AAV particle was generated in a parallel experiment. This AAV particle 
contains a section of the LacZ sequence. For each transfection (pAAV-CaMKIIG2-
mCherry/pAAV-CaMKIIJ3-mCherry/pAAV-LacZ-mCherry) two T175 flasks of 293AAV cells were 
grown to 70-80% confluence. Initially, two tubes (A-B) for each of the transfections were set 
up according to Table 4.2 and incubated for 5 min. Following this, tube A was incorporated 
into tube B, mixed gently, and incubated for a further 5 min. 
 
Table 4.2: Summary for transfection of 293AAV cells using Lipofectamine 3000.  
 
 Component 2 X T175 Flasks 
Tube A DJ 27.6 µg 
pHelper 27.6 µg 
CaMKIIG2/CaMKIIJ3/LacZ (control) 27.6 µg 
P3000 Reagent 172.5 µL 
DMEM (no serum) Adjust total volume to 3000 µL 
   
Tube B Lipofectamine Reagent 250 µL 
DMEM (no serum) 2750 µL 





Each transfection mix was added drop by drop to the appropriate T175 flask while swirling 
gently. The flasks were returned to the incubator at 37°C with 5% CO2, and incubated for 72 
hours. At this time, the flasks were viewed under a ZOE Fluorescent Cell Imager (cat.no. 
1450031, BIORAD) with red filter and photos captured (Figure 4.9). The red glowing cells are 
indicative of mCherry expression and a successful transfection of pAAV-CaMKIIG2-mCherry (A), 
pAAV-CaMKIIJ3-mCherry (B) and pAAV-LacZ-mCherry (C). Each flask was then prepared for 





Figure 4.9: Transfection of 293 AAV cells for viral production. Cells were co-transfected with DJ, helper 
plasmid and either pAAV-CaMKIIG2-mCherry (A), pAAV-CaMKIIJ3-mCherry (B), LacZ-mCherry (C) or 
nothing (D). 72-hrs post-transfection, cells were viewed and photos captured using the ZOE Fluorescent 
Cell Imager (cat.no. 1450031 BIORAD). A positive transfection was confirmed by red glowing cells 
indicating mCherry expression.  
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4.2.2.2 AAV Purification 
 
72 hrs post-transfection 0.5 M EDTA was added to the flask to alleviate cell adhesion and pull 
cells into suspension. The media was harvested into a 15 ml conical tube and centrifuged at 
1000 x g for 5 mins to pellet transfected cells. The pellet was resuspended in 2.5 ml serum-
free DMEM and subjected to four rounds of freeze/thaw cycling using dry ice-ethanol bath 
and 37°C water bath. The tube was centrifuged at 10,000 x g for 10 mins and the AAV-
containing supernatant collected and transferred to a fresh 15 ml tube. 
 
To extract AAV particles from cells at 72 hrs post-transfection, the ViraBind AAV Purification 
Kit (cata.no. VPK-140 CELLBIOLABS) was used. 25 µL of AAV Reagent A was added to 2.5 ml of 
viral supernatant and incubated at 37°C for 30 mins. The tube was centrifuged at 5000 x g for 
15 mins and the supernatant transferred to a fresh 10 ml tube. Following this, 125 µL of pre-
warmed (37°C) Reagent B was added to the viral supernatant and incubated at 37°C for 30 
mins. The tube was centrifuged at 10,000 x g for 10 mins and the supernatant transferred to 
a sterile 15 ml conical tube.  
 
The AAV-containing supernatant was resuspended in 300 µL of Purification Matrix and mixed 
at room temperature for 30 mins on an orbital shaker. Immediately after, the tube was 
centrifuged at 1000 x g for 10 mins to pellet the purification matrix. The supernatant was 
discarded and the purification matrix was washed with 2.5 ml purification buffer. The tube 
was centrifuged at 1000 G for 10 mins and the supernatant carefully removed. 0.5 ml of 
elution buffer was added to extract purified AAVs and the mixture was incubated on an orbital 
shaker for 10 mins at 4°C. Post-incubation, the conical tube was centrifuged at 1000 x g for 10 
mins and the eluted AAV-containing supernatant carefully collected. 
 
The supernatant was applied to the sample reservoir in a centrifugal concentrator and 
centrifuged at 2000 x g for 5 mins. Flow-through was discarded until 100 µL remained in the 
sample reservoir. 400 µL PBS was added to the concentrator and centrifuged again at 2000 x 
g until 100 µL remained and this step repeated one more time. The sample reservoir was 
inverted over a sterile 1.5 ml microcentrifuge tube and centrifuged at 1000 x g for 30 secs to 
collect concentrated AAV sample. A 5 µL sample of each AAV was taken to calculate the titre 
and the remaining AAVs stored at -80°C. 
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4.2.2.3 AAV Titration 
 
To calculate the physical titre for each AAV, qPCR using SYBR Green PowerUp was carried out. 
The AAV2 inverted terminal repeat (ITR) sequence was targeted by qPCR as the viral marker; 
ITR primer pair fwd: 5’-GGAACCCCTAGTGATGGAGTT-3’, rev: CGGCCTCAGTGAGCGA-3’.  
 
Firstly, the 5 µL samples kept aside were diluted 1:80 and 1:5000 with DEPC-treated water. 
Each diluted sample was set up for qPCR as shown in Table 4.3. Additionally, another set of 
reactions were set up using plasmid standards ranging from concentrations 2 X 103 molecules 
/ µL to 2 X 109 molecules / µL.  
 
Table 4.3: qPCR components for calculating virus titre 
 
PCR Component Volume (µL) per reaction 
SYBR Green 10 
100 µM ITR fwd 0.1 
100 µM ITR rev 0.1 
DEPC-treated water 4.8 
Sample 5 
 
Each reaction was carried out in triplicate. 15 µL qPCR mastermix was added to each well in a 
96 well plate and kept on ice. 5 µL of diluted AAV sample or standard was added to a well and 
the plate lid attached. The 96 well-plate was spun on a benchtop centrifuge and loaded into 
the Applied Biosystems StepOne Plus RTPCR system and PCR performed under the conditions 
shown in Table 4.4. 
 
Table 4.4: PCR conditions for AAV titration 
 
Denaturing 98°C – 15 sec  
X 40 cycles Annealing 63°C – 30 sec 
Elongation 72°C – 30 sec 
 
The mean cycle threshold (CT) value was calculated between each of the triplicate reactions 
for standards and diluted samples. A standard curve was constructed from known standards 
on Graphpad Prism. The CT value for each diluted sample was inserted into the standard curve 
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equation to calculate x as shown in example equation 1. The x value was log transformed and 
multiplied by the dilution factor to transform the units into genome copies per ml (GC/ml). 
 
Equation 4.1:  
 
Y(CT) = -2.997x + 37.85 
X = (CT – 37.85)/-2.997 
 
 
4.2.2.4 Transfection of CaMKII-mCherry into HCASMCs and HUVECs 
 
Human coronary artery smooth muscle cells (HCASMCs), human umbilical vein endothelial 
cells (HUVECs) and human coronary artery endothelial cells (HCAECs) were cultured in 
specialised growth medium with 10% fetal bovine serum (FBS) and 1% pen/strep as described 
in Section 2.2.1. 
 
24 hr before transduction, HCASMCs and HUVECs were seeded into individual 6-well plates at 
a concentration of 5 x 105 cells/ml. 20 µL of respective media containing  5x1012 PFUs of either 
CaMKIIG2, CaMKIIG6 or control AAV was added to each well drop by drop. Cells were returned 
to the incubator for 48 hrs. After this time, HUVECs and HCASMC were harvested for total RNA 
and RT-PCR was performed targeting huV1 as previously described in Section 2.2.1. 
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4.2.3 Animal Work 
 
Fourteen ApoE-/-CaMKIIG-/- mice were housed at the Hercus-Taieri Research Unit (HTRU) 
under a 12:12 hr lighting schedule with ad libitum access to food and water.  At 14-weeks of 
age, mice were switched from a regular chow diet (5 % energy from fat) to a high-fat diet 
(HFD) (40 % energy from fat). At 16-weeks of age, the left carotid artery (LCA) was accessed 
by surgery and ligated with a suture to disrupt blood flow and promote atherogenesis. AAVs 
expressing either CaMKIIG2-mCherry or control-mCherry were introduced to the left carotid 
artery of the mice. The surgical manipulation of the carotid artery and AAV instilment in these 
mice was approved by the University of Otago Animal Ethics Committee (AEC) (19-58). 
 
4.2.3.1 Carotid artery surgery and AAV overexpression 
 
Prior to induction of anaesthesia, analgesia was provided to each mouse by subcutaneous 
injection of carprofen (5 mg/kg). At the time of surgery, anaesthesia of the mouse was induced 
by intraperitoneal (IP) administration of a ketamine (75mg/kg) and medetomidine (1mg/kg). 
After surgical anaesthesia was induced and confirmed by the pedal-withdrawal reflex, the fur 
around the neck and clavicle was removed by depilatory cream and a local injection of 
lignocaine (5 mg/kg) administered. The mouse was then transferred to the operating theatre 
for surgery employing full aseptic techniques. 
 
An incision was made in the mouse neck midline from the level of the sternum to the 
mandible. Using blunt dissection, the skin was separated from underlying submandibular 
gland and other soft tissues. The sternomastoid muscle was located under the submandibular 
gland and retracted to the left side to access the bifurcation of the LCA. The LCA was freed of 
the vagus nerve and other surrounding tissues. A 6-0 silk suture was placed around the artery 
and a piece of nylon with a diameter of 400 µm below the level of the bifurcation was tied to 
impede blood flow. The piece of nylon was removed so that the area ligated was similar 
between mice. Although this manipulation is a partial ligation, it will be referred to just as 
ligated artery in the following sections. 
 
50 µL of 30% Pluronic f-127 suspending either CaMKII or control (3X108 PFU gel) was applied 
to the adventitial surface of the LCA. The sternomastoid muscle and submandibular gland was 
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carefully replaced and the skin wound closed by application of tissue glue. Anaesthesia was 
reversed with subcutaneous administration of antisedan (5 mg/kg). Additionally, a saline bolus 
(1 ml) was administered to maintain the hydration status of the mouse. The recovery of each 
mouse was closely monitored for the next 4 hrs in a warming chamber before returning to the 





Four-weeks post-surgery (20-weeks of age), mice were euthanised by CO2 overdose at a flow 
rate of 8.5 L/min. Once breathing had ceased, mice were left for an additional 2 mins of CO2 
and then death was confirmed by the pedal withdrawal reflex. Each mouse was set on a 
dissection board and cardiac perfusion was carried out as described in Section 2.2.2. 
 
After tissue fixation by cardiac perfusion of 4% PFA the aortic tree was located in the thoracic 
cavity and excised from the mouse as previously described in Section 2.2.2.1. The carotid 
arteries were cut off the aortic tree above the level of the aortic arch and above the carotid 
artery bifurcation as shown in Figure 4.10. 
 
The left-ligated and AAV-transduced carotid artery was embedded alongside the non-ligated 
contralateral right artery. The carotid arteries were orientated with the external and internal 
carotid bifurcation facing down against the block mould. In this way, sections were cut from 
the carotid bifurcation toward the aortic arch. The block was trimmed at 20 µm until the two 
lumens of the internal and external carotid arteries converged. A 5 µm section was collected 








Figure 4.10: Intact aortic arch from a control-mouse at 20-weeks age. At 20-weeks age mice were 
euthanised by CO2 overdose and then perfusion fixed with 4% PFA. Excess adipose tissue was trimmed 
away from the aortic arch and associated branches. Black dotted line shows outline of the aortic tree. 
White dotted lines show where the carotid artery was dissected.  Anatomy of the aortic tree indicated 
by blue arrows; right internal carotid artery (RICA), right external carotid artery (RECA), right carotid 
artery (RCA), right subclavian artery (RSA), brachiocephalic artery (BA), left subclavian artery (LSA), left 
carotid artery (LCA), left external carotid artery (LECA) and left internal carotid artery (LICA). Red arrows 
indicate regions of foam cell lesion growth. Scale bar = 1000 µm. 
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4.2.3.2 Fluorescent microscopy 
 
Whole transverse carotid sections were illuminated using a CoolLED fluorescence illuminator 
on an Olympus BX-50 (Olympus Corporation, Tokyo, Japan) compound widefield fluorescence 
microscope and digitally photographed with a Spot-RT slider (SPOT Imaging Solutions: 
Diagnostic Instruments, Inc., Sterling Heights, MI) cooled digital microscope camera. 






All data was analysed on GraphPad Prism 8 ad is expressed as mean r SEM. Significant 





4.3.1 Validation of CaMKIIG2-/control-mCherry AAV particles in vitro. 
 
Before any AAV particles expressing CaMKIIG2- or control-mCherry were transduced into the 
carotid arteries of ApoE-/- mice, they were first tested in vitro. The primary objective of 
producing the AAV particles was to over-express CaMKIIG2 in the carotid artery, so, a human 
vascular cell culture model was used mimic cell groups more closely.  
 
Human coronary artery smooth muscle cells (HCASMCs) and human umbilical vein endothelial 
cells (HUVECs) were cultured, as previously described, and 5 x 108 PFU of either CaMKIIG2-, 
CaMKIIG6-, or control-mCherry was transduced and incubated for 24 hr. An additional AAV 
variant CaMKIIG6, generated in a previous experiment was also included to serve as an 
additional control of a validated variant.  Post-24 hr, total RNA was extracted and RT-PCR 
performed targeting huV1 (G2  and G6 variants) in a thermocycler. Products of PCR were 
visualised by agarose gel electrophoresis (Section 2.2.3). 
 
Figure 4.11 shows the relative mRNA level of CaMKIIG2- and CaMKIIG6- in human vascular cells. 
In both HCASMCs and HUVECs, the presence of a band at 130 bp and 190 bp, indicated by the 
blue arrows is indicative of the CaMKIIG2 and CaMKIIG6 transcript, respectively. In HCASMCs 
and HUVECs transduced with CaMKIIG2 there was an observed increased intensity in band 
product. In addition, CaMKIIG6 transduced HCASMCs and HUVECs had a band present at 190 
bp, which was not present in the other groups. These findings validate that the AAV-CaMKIIG2- 








Figure 4.11: DNA agarose gel showing CaMKIIG variant levels in HUVECs and HCASMCs transduced 
with either control-, CaMKIIG2- or CaMKIIG6-mCherry.  HUVECs and HCASMCs were left untreated or 
transduced with 5 x 10
8
 PFU of either control-, CaMKIIG2- or CaMKIIG6-mCherry and incubated for 24 hr. 
Total RNA was extracted and 100 ng cDNA used in RT-PCR targeting the huV1 primer set. PCR products 
were loaded into a 1.5% agarose gel and electrophoresis run at 90 V for 1 hr. 100 bp DNA marker 
(Invitrogen cat.no. 15628019). 
  
 128 
4.3.2 Ligation of the left carotid artery (LCA) of ApoE-/-CaMKIIG-/- mice causes 
gross morphological changes to the vascular wall. 
 
At 16-weeks of age, the LCA of ApoE-/-CaMKIIG-/- mice fed a HFD for the previous 2-weeks was 
surgically accessed and ligated to increase shear stress and promote atherogenesis. 5 x 108 
PFU of either control- or CaMKIIG2- was applied to the arterial tissue via a pluronic gel. The 
incision was closed and the mice monitored over recovery before being returned to animal 
housing. Eight mice did not survive the experiment. In the two-day post-surgical monitoring 
period, four mice from each control and dKO group were euthanised for welfare reasons. 
These mice showed signs of head nodding, irritation, vocalisation and ataxia indicative of some 
degree of stroke. 
 
At 20-weeks of age, the mice were perfused fixed as described in Section 3.2.1.2 and the left 
ligated and right non-ligated carotid artery dissected and laid flat under a dissection 
microscope. Figure 4.12 shows four sets of left and right carotid arteries from ApoE-/-CaMKIIG-
/- mice treated with either CaMKIIG2- (CaMKIIG2) or control-mCherry (control) AAVs (n = 4/8). 
What became immediately striking was the variation in the appearance of the left ligated 
carotid artery. In both control and CaMKIIG2 groups there was a range of atherosclerosis from 
small pockets of foam cell lesion growth to extensive atherosclerotic lesions and vascular 
remodelling.  Interestingly, in the CaMKIIG2 treated mice,  three out of eight left ligated carotid 
arteries had evidence of thrombolysis, indicated by the appearance of clotted blood through 
the vascular wall (Figure 4.12E & H).  
 
In contrast, by gross observation, the non-ligated right carotid artery had a more translucent 
and this was consistent between and across groups. Figure 4.12I highlights the importance of 
distinguishing between perivascular adipose tissue, fat on the outside of the artery, and foam 






Figure 4.12: Dissected left-ligated and right carotid arteries from ApoE-/-CaMKIIG-/- mice treated with 
either control- or CaMKIIG2-mCherry. Mice were perfusion fixed with 4% PFA and left (LCA) and right 
carotid arteries(RCA) dissected. Anatomical features of the carotid artery include foam cell lesions, 
perivascular adipose tissue, thrombus and ligation tie indicated by red arrows and labels. Scale bar for 
top panels = 1000 µm, bottom photo = 200 µm.  Representative panels show four out of eight mice for 
each treatment group (n = 8). 
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4.3.3 Ligation of the carotid artery in ApoE-/-CaMKIIG-/- mice rapidly promotes 
foam cell lesion development and arterial wall remodeling. 
 
AAV-transduced left-ligated and right carotid artery of ApoE-/-CaMKIIG-/- mice were embedded 
in paraffin wax as described in Section 4.2.3.2. The carotid artery was sectioned in a cross-
sectional plane from the bifurcation of the external and internal carotid artery toward the 
aortic arch. The non-ligated right carotid artery was used in a later experiment to assess 
specificity of mCherry expression. 
 
Figure 4.13-14 are representative images of sections collected along the carotid artery of four 
mice transduced with either control- or CaMKIIG2-mCherry, respectively (n = 8 total). In the 
left carotid artery of mice transduced with control-mCherry, there were variable amounts of 
foam cell lesions present to different degrees of progression. In Figure 4.13A there is foam 
cell lesion present around the majority of the inner wall of the carotid artery. Furthermore, 
foam cell lesions are also present in the subsequent section (A2) but then are not present to 
the same extent in the last two sections (A3-4). Contrast this with representative section D1-
4 where there is an area of foam cell lesion development present in the first section but no 
observable lesions in the subsequent three sections (D2-4). 
 
In the sections from mice transduced with CaMKIIG2-mCherry, there was atherosclerosis 
present (Figure 4.14). Foam cell lesions present in the carotid artery, ranging from medium 
size lesions that occupied one side of the vessel wall (B2), to large continuous lesions, which 
occupied a large area of the lumen space (A2). Like the control mice, in the latter section, foam 
cell lesion content seemed to decrease dramatically and in some sections in these mice there 
was no observable lesion growth (Figure 3.14A4, B3, B4, D4). Interestingly, in Figure 3.14C1-
C4, instead of the characteristic grey ‘soap bubble’ like cells composing the lesions there was 
a growth in the lumen which was a combination of brown and pink stained tissue indicating 
VSMCs and extracellular matrix. This is likely inward remodelling (proliferation of VSMCs) in 











Figure 4.13: Foam cell lesions in the left-ligated carotid artery of ApoE-/-CaMKIIG-/- mice transduced 
with control-mCherry. At 16-weeks of age ApoE-/-CaMKIIG-/- mice underwent surgical ligation of the 
left carotid artery. 5 x 108 PFUs of control-mCherry was applied to the left carotid artery in a pluronic 
gel (20%). Mice were euthanised at 20-weeks and perfusion fixed with 4% PFA. Four 5 µm section were 
collected in 200 µm intervals from the internal and external carotid bifurcation toward the aortic arch 
(1-4). Sections were stained with Verhoeff van Gieson. Shown above in each panel (A-D) is a 
representative of the carotid artery sections from four out of eight control-treated mice. Red arrows 








Figure 4.14: Foam cell lesions in the left-ligated carotid artery of ApoE-/-CaMKIIG-/- mice transduced 
with CaMKIIG2-mCherry. At 16-weeks of age ApoE-/-CaMKIIG-/- mice underwent surgical ligation of the 
left carotid artery. 5 x 10
8
 PFUs of CaMKIIG2-mCherry was applied to the left carotid artery in a pluronic 
gel (20%). Mice were euthanised at 20-weeks and perfusion fixed with 4% PFA. Four 5 µm sections were 
collected in 200 µm intervals from the internal and external carotid bifurcation toward the aortic arch 
(1-4). Sections were stained with Verhoeff van Gieson. Shown above in each panel (A-D) is a 
representative of the carotid artery sections from four out of eight control-treated mice. Red arrows 




4.3.4 Detection of mCherry fluorescence in the carotid arteries of ApoE-/-
CaMKIIG-/- mice transduced with CaMKIIG2- and control-mCherry.  
 
To confirm a successful AAV transduction, the left-AAV-transduced and right carotid artery of 
ApoE-/- CaMKIIG2-/-  were analysed for mCherry fluorescence.  CaMKIIG2 and control AAV 
particles contained a red mCherry tag that allowed detection of virus transduction in the 
vascular wall. Four sections of the left and right carotid arteries of mice were cut along the 
length of the carotid artery. The right non-ligated artery was used to identify whether the AAV 
transduction was specific to the left carotid artery. Carotid sections were illuminated using a 
CoolLED fluorescence illuminator on an Olympus BX-50 (Olympus Corporation, Tokyo, Japan) 
and digital images captured.  
 
Figure 4.15 shows the left-ligated and right carotid artery of a CaMKIIG2 mouse both, stained 
with VVG (1.A-D & 3.A-D) and imaged under a fluorescent microscope (2.A-D & 4.A-D). There 
was red fluorescence in the vessel wall of the left carotid artery sections indicating mCherry 
expression. Furthermore, in the right non-treated sections, there was also red fluorescence 
(4.A-D). This suggests the virus was not localised to the left carotid artery. Interestingly, there 
was no red fluorescence in the foam cell lesion region of the sections. A carotid artery and 
aortic sinus section from an untreated control mouse was also imaged. In these control 
sections, under low emission there was still some red fluorescence. This was surprising and 






Figure 4.15: Detection of mCherry fluorescence in the left ligated and right non-ligated carotid artery of 
control and CaMKIIG2 mice. At 16-weeks of age ApoE-/-CaMKIIG-/- mice underwent surgical ligation of the 
left carotid artery. 5 x 108 PFUs of CaMKIIG2-mCherry was incubated over the left carotid artery in a pluronic 
gel (20%). Mice were euthanised at 20-weeks and perfusion fixed with 4% PFA. Four 5 µm sections of the 
left and right carotid artery were collected in 200 µm intervals from the internal and external carotid 
bifurcation toward the aortic arch (1.A-D left carotid, & 3.A-D right carotid). Carotid sections were 
illuminated using a CoolLED fluorescence illuminator on an Olympus BX-50 (Olympus Corporation, Tokyo, 
Japan) compound widefield fluorescence microscope and digitally photographed with a Spot-RT slider 
(SPOT Imaging Solutions: Diagnostic Instruments, Inc., Sterling Heights, MI) cooled digital microscope 
camera (2.A-D left carotid, 4.A-D right carotid, 5.A control carotid, 5.B control aortic sinus. Red arrows 
indicated foam cell lesions. The red dotted line shows the vessel wall region (5B). Scale bar = 200 µm. 
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4.3.5 CaMKIIG2 has no effect on vessel wall hypertrophy in response to ligation 
of the left carotid artery in ApoE-/-CaMKIIG-/- mice. 
 
The primary focus of the current experiment was to identify the impact of CaMKIIG2 on foam 
cell lesion growth in the carotid arteries of ApoE-/-CaMKIIG-/- mice. CaMKIIG2 has been shown 
to play a role in proliferative response of VSMCs after arterial injury [219]. Therefore, firstly it 
was measured if CaMKIIG2 promotes hypertrophy of the vessel wall after ligation of the left 
carotid artery.  
 
The left carotid artery of mice from control- and CaMKIIG2-mCherry groups was sectioned and 
stained with VVG as previously described (Section 4.2.3.2). Vessel wall width was indicated by 
the boundary of the IEL stained black (Figure 4.13-14). In both control and CaMKIIG2 groups, 
there were sections containing extensive hypertrophy of the vessel wall (Figure 4.13A1 & C2, 
Figure 3.14C2 & D3). In contrast there were also sections that displayed no hypertrophy and 
the IEL remained tightly bound (Figure 13B3 & D4, Figure 14A4 & D4). 
 
Eight regions of the vessel wall were measured on all four sections in both mice groups and 
the mean was calculated. There were no significant differences in vessel wall width in the 0 
µm, 200 µm, 400 µm and 600µm section between CaMKIIG2 and control groups (N.S, p = 0.3, 
0.5, 0.9,0.6, respectively, n = 8) (Figure 4.16). Furthermore, vessel width was around 30 µM in 
both groups and did not change over the length of the carotid artery. This indicates that 












Figure 4.16: Vessel wall width quantification in the left-ligated carotid artery of ApoE-/-CaMKIIG-/- 
mice transduced with control- or CaMKIIG2-mCherry. Four 5 µM sections were cut in 200 µm intervals 
throughout the carotid artery from the internal and external carotid bifurcation toward the aortic arch 
(0 µM, 200 µM, 400 µM, 600 µM). Sections were stained with VVG and eight measurements of the 
vessel wall width were taken per section and the mean calculated. Graph shows vessel wall width (µM) 
as mean r S.E.M. Not significant (N.S) as determined by unpaired Students t-test (n = 8). 
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4.3.6 Examining the effect of CaMKIIG2 on foam cell lesion growth in an 
accelerated model of atherosclerosis. 
 
Next, it was investigated if CaMKIIG2.has any effect on foam cell lesion growth in the left-
ligated carotid arteries of ApoE-/-CaMKIIG-/- mice. Carotid artery sections were stained with 
VVG and foam cell lesion area was measured (0 µm, 200 µm, 400 µm, 600 µm sections). Shown 
in Figure 4.13-14 and indicated by the red arrows are foam cell lesions present in the carotid 
artery of ApoE-/-CaMKIIG-/- mice transduced with either control- or CaMKIIG2-mCherry, 
respectively. There was foam cell lesion development in the carotid artery of both groups and 
lesions ranged in progression.  
 
Although the mean foam cell lesion area was higher across all four sections in the CaMKIIG2 , 
there were no significant differences compared to control group (n = 8, N.S, p = 0.4, 0.5, 0.2, 
0.3, respectively) (Figure 4.17). The area under the curve was measured across all four 
sections to calculate foam cell lesion volume. In control and CaMKIIG2 mice the mean foam cell 
lesion volume was 387 r 92 µm3 and 594 r 128 µm3. When each group was compared there 





Figure 4.17: Foam cell lesion quantification in the left-ligated carotid artery of ApoE-/-CaMKIIG-/- mice 
transduced with control- or CaMKIIG2-mCherry. Four 5 µM sections were cut in 200 µm intervals 
throughout the carotid artery from the internal and external carotid bifurcation toward the aortic arch 
(0 µM, 200 µM, 400 µM, 600 µM). Sections were stained with VVG and foam cell lesion area measured 
in each section (Above). The area under the curve was measured to calculate foam cell lesion volume 
(Below) Data on graphs is presented as mean foam cell lesion r S.E.M. Not significant (N.S) as 
determined by unpaired Students t-test (n = 8).  
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4.3.7 Evaluating stenosis in the ligated carotid arteries of ApoE-/-CaMKIIG-/- 
mice transduced with CaMKIIG2- and control-mCherry.  
 
The CaMKIIG2 mice did not show a significant increase in foam cell volume compared to 
control, regardless of having higher mean foam cell areas for each set of sections (Figure 4.17). 
Even though foam cell lesion was the primary investigation, it was next identified if there were 
differences in stenosis along the carotid artery between control- and CaMKIIG2 mice. Stenosis 
is a useful functional measurement as it provides an indication of the physical obstruction the 
foam cell lesion relative to the size of the lumen.  
 
The inner circumference of the left-ligated carotid artery sections from control- and CaMKIIG2-
mCherry mice was measured to calculate lumen area. Using the foam cell lesion area data and 
lumen area stenosis (%) was calculated as shown in Figure 4.18. Both groups showed a similar 
trend in stenosis as seen in foam cell lesion area with an increase from 0 µm to 200 µm and 
then a steady decline to 600 µm. The mean stenosis percentages in the control- group was 
10.4 r 4.3 % (0 µm), 25.4 r 9.8 % (200 µm), 16.3 r 9.4 (400 µm) and 10.5 r 9.8 % (600 µm). In 
comparison the mean stenosis of the CaMKIIG2 group was 27.7 r 12.3 % (0 µm), 43.5 r 12.2 % 
(200 µm), 32.4 r 11.5 (400 µm) and 19.7 r 11.6 % (600 µm). Although mean stenosis in 
CaMKIIG2 group was higher than control group across all four sections, there were no 









Figure 4.18: Stenosis quantification in the left-ligated carotid artery of ApoE-/-CaMKIIG-/- mice 
transduced with control- or CaMKIIG2-mCherry. Four 5 µm sections were cut in 200 µm intervals 
throughout the carotid artery from the internal and external carotid bifurcation toward the aortic arch 
(0 µm, 200 µm, 400 µm, 600 µm). Sections were stained with VVG. The inner circumference of the lumen 
was measured to calculate lumen area. Foam cell lesion area was divided by lumen area to calculate 
stenosis (%). Data on graphs is presented as mean foam cell lesion r S.E.M. Not significant (N.S) as 





In this final chapter, an AAV-mediated overexpression approach was employed to identify the 
contribution of CaMKIIG2 to foam cell lesion development. CaMKIIG2-expressing AAV particles 
were introduced to the left-ligated carotid artery of ApoE-/-CaMKIIG-/- mice. Ligation of the 
carotid artery alters blood flow and shear stress, creating a local milieu that promotes 
atherogenesis [34, 35, 250-252]. After 4-weeks the carotid arteries were processed for 
histology and sections analysed for foam cell lesion area/volume (µm2, µm3), stenosis (%), and 
vessel wall width. 
 
Foam cell lesions were variable in the carotid arteries of CaMKIIG2- and control-mCherry mice, 
indicated by the high SEM for mean lesion area for each section (Figure 4.17). In both groups, 
lesions ranged from small pockets of growth containing a small number of foam cells, to 
extensive foam cell lesions, that had a more advanced phenotype (Figure 4.13-14). This 
included the appearance of lipid pool accumulation and fibrous cap formation (Figure 4.13C2, 
& Figure 4.14A2, B1, A2). This is likely to reflect differences in consumption of the high-fat 
diet between mice. LDL-C is the major risk factor for the development of atherosclerosis [14-
16]. LDL-C entry and exit in foam cells is tightly regulated and when lipid accumulation exceeds 
storage capabilities, lipid pooling occurs [62-64].  
 
Next, it was analysed what influence CaMKIIG2-mCherry transduction had in the surgically-
induced pro-atherogenic environment. After four-weeks of incubation there was red 
fluorescence detected in the vascular wall of the left ligated carotid artery of both control- 
and CaMKIIG2-mCherry groups (Figure 4.15). This indicated the AAVs had successfully 
transduced into the vascular wall. CaMKIIG2-mCherry mice had increased foam cell lesion area 
in the four sections analysed along the length of the carotid artery compared to control-
mCherry mice. However, when this data was compared to control group, there were no 
significant differences in foam cell area or volume (Figure 4.17). The lack of significance in 
lesion area and volume between groups is likely to reflect a low n number. Initially, twenty 
animals were randomly allocated into either control-mCherry, or CaMKIIG2-mCherry groups (n 
= 10). However, problems with recovery meant four mice across both groups were euthanised 
for welfare reasons, which will be discussed later. With the low n numbers and trending 
significance in mind, this data suggests CaMKIIG2 is likely to promote foam cell lesion 
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development, however, a full sample size is required to determine whether there is a 
significant effect. 
 
To gain some idea of the functional impact foam cell lesions were causing on blood flow in the 
carotid artery, stenosis was calculated. Stenosis is a useful measurement as it calculates what 
area of the lumen is occupied by foam cell lesions. This is important as impeding blood flow is 
a major mechanism of ischaemic injury such as stroke [253, 254]. For example, if lesion area 
is extensive but lumen area is large, there is less stenosis than if that same lesion was present 
in a smaller artery. Stenosis (%) along the length of the carotid artery showed a similar trend 
to foam cell lesion area in both groups. This was an initial increase 0 µm – 100 µm followed by 
a reduction over the 400 µm and 600 µm measurement points (Figure 4.17). Although there 
were no significant differences between groups, likely due to low n numbers, the stenosis area 
was higher on average across each measurement point of the carotid artery in CaMKIIG2 
groups.  
 
In Chapter 3, CaMKIIG knock out resulted in a reduction in foam cell lesion development in the 
aortic sinus. Therefore, in this experiment, it was hypothesised CaMKIIG2 would augment 
carotid artery foam cell lesion development. The CaMKIIG isoform is the predominant subtype 
expressed in cells of the vascular wall and has been linked to endothelial and VSMC pathology 
[181, 212, 218, 219, 255]. From what is known about variant specific functions the G2 has 
shown roles in VSMC proliferation and migration whereas G6 has been associated with 
endothelial dysfunction [212, 219, 220]. In these studies, the pathologies were examined in 
an independent setting, however, the mechanisms involved collectively contribute to the 
pathogenesis of atherosclerosis [13]. It is reasonable to then speculate that CaMKIIG2 is most 
likely contributing to foam cell lesion growth through its effects in VSMCs rather than in 
endothelial cells. This is also evidenced as mCherry fluorescence was localised to the media 
layer of the artery wall rather than cells on the luminal surface (Figure 4.15). In the production 
of the CaMKIIG2 , an additional variant G6 was generated in parallel. In the future, it would be 
interesting to transduce CaMKIIG6, a variant known to promote endothelial dysfunction, into 
the left-ligated carotid arteries in a similar manner to identify and compare the relative 
contribution to foam cell lesion development.  
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Across the foam cell lesion area and stenosis data, what was evident was the variation in both 
groups suggesting optimisation of the model is still required. Already, it has been discussed 
that differences in the amount of HFD eaten are likely to contribute to more advanced lesion 
characteristics, and this is the same with foam cell lesion progression [162, 256]. Another 
reason for the variation in data is the extent of ligation. For the purpose of these experiments, 
ligating the carotid artery was used to alter shear stress to promote endothelial dysfunction 
and atherogenesis [249-251].  In the surgical procedure, ligation of the left-carotid artery was 
achieved by tying a piece of silk around the artery and a piece of nylon, which was later 
removed, so the area reduced was the same between mice (Section 4.2.3.1). However, the 
manipulation was carried out under microscope on a relatively small region of the mouse 
aortic tree, so it is likely there is an element of surgical error. In addition, the initial ligations 
may have been similar at the time of surgery, but under conditions of high pressure, pulsatile 
flow could have loosened the ligation over the following four-week period. Together, the 
variation in how individual mice respond to HFD and the potential surgical error result in a 
high SEM in both groups suggesting further refinement of the technique is required.  
 
Further to these technical issues, the variation in data could also be confounded by sex 
differences. Male and female data groups were pooled in this study. Female ApoE-/- mice on a 
C57/Bl6 background develop atherosclerosis at a faster rate than males [236, 237, 239] (Figure 
3.14). Because of these sex differences in lesion progression, atherosclerosis assessment in 
the ApoE-/- mouse should be grouped as males and females. In the case of this experiment, 
mice were fed a HFD and the left carotid artery ligated to promote atherosclerosis. Both diet 
and surgical manipulation are strong stimuli for atherosclerosis so it is possible sex as a driver 
was overridden by these other factors over this four-week period, however it cannot be 
discounted [162, 256, 257]. In future experiments, increasing the n number to allow for sex-
dependent analysis of data may also help to reduce variation.   
 
An important aspect of the model used in this study is that the ligation was performed on an 
atherosclerotic background (ApoE-/-CaMKIIG-/-). Without the elevated LDL-C levels, wild-type 
mice do not develop atherosclerosis even with surgical manipulation [158, 249, 258, 259]. 
Carotid ligations are also used in models of flow remodeling. In these vascular diseases, the 
structure of the vascular wall changes to compensate for changes in flow and blood pressure. 
Collectively, these studies have used a range of approaches from partial to complete ligations 
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and have applied the ligation to different regions of the carotid branches including the internal 
and external carotid artery [249, 259-262]. In wild-type mice, ligation of the carotid artery 
causes injury to the vascular wall promoting the release of inflammatory mediators which 
promote VSMC phenotype switch from contractile to synthetic [263]. The synthetic 
phenotype is characterised by increased proliferation, migration and ECM production [72]. 
This leads to the expansion of the intimal region of the artery wall, termed neo-intima, as 
VSMCs migrate to the intima and generate ECM [262].  
 
With these other ligation approaches in mind, it was expected that there may be some 
elements of vascular remodeling independent of foam cell lesion growth and, indeed, this was 
observed in some of the carotid sections (Figure 4.13-14). It was important we could 
differentiate between foam cell lesion development and vascular remodeling [264]. This was 
achieved by using the VVG stain which stained foam cells grey and VSMCs and ECM brown 
and pink, respectively. Vascular remodeling in both groups of mice ranged from hypertrophy 
of the media wall layer (Figure 4.13 B4 & C3) to striking neo-intima (Figure 4.14 B1 & C4). 
formation shown by pink and brown staining. As we saw some remodeling in the carotid artery 
sections across both groups, vessel wall width was measured to identify if CaMKIIG2 
contributed to remodelling in this atherosclerotic model (ApoE-/-). CaMKIIG2 had no significant 
effect on vessel wall hypertrophy (Figure 4.16). This is in contrast with the current literature 
that has shown in models of flow remodelling that CaMKIIG2 mediates the proliferative 
response in response to arterial injury [181, 220, 259]. The fact this difference was not seen 
could reflect a volatile environment that promotes lesion formation over vascular 
remodelling. 
 
The ligation method is clearly a sensitive technique. In the current experiment a partial ligation 
was applied to increase shear stress to promote atherogenesis [248, 250-252]. In other non-
atherosclerotic models, more extensive ligations are used to induce vascular remodeling, 
which suggests there is a fine line for using this technique to study the pathogenesis of 
atherosclerosis. Both diseases involve similar mechanisms for pathogenicity (e.g. VSMC 
proliferation) so it is unlikely foam cell lesion can occur without some level of vascular 
remodeling. In this experiment, significant ligations to the carotid artery resulted in adverse 
effects. In the two-day post-operative recovery period four mice across both groups displayed 
neurological issues including fatigue and ataxia and mice were euthanised for welfare reasons. 
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These neurological issues are phenotypes commonly seen in stroke. Although stroke was not 
examined by post-mortem examination, there was some evidence in the 20-week carotid 
arteries to suggest this is likely. In the carotid artery of some mice there was extensive 
atherosclerosis and the presence of clotted blood (Figure 4.12E & H), indicating 
thromboembolytic activity, a common mechanism for stroke [265, 266]. Regardless of the 
small surgical risks associated with ischaemic injury, the carotid artery ligation serves as an 
excellent tool for studying the pathogenesis of atherosclerosis. 
 
The mCherry tag was identified under fluorescent microscope to check for a positive 
transduction four-weeks post-surgery (Figure 4.15). Carotid artery sections from the control- 
and  CaMKIIG2 groups displayed bright red fluorescence in the vascular wall, indicative of a 
positive AAV transduction. AAV delivery was in a pluronic gel and applied locally to the left-
ligated carotid artery. The non-ligated contralateral artery served as a control to identify if the 
AAV had been delivered specifically to the left carotid artery. Detection of red fluorescence in 
the medial wall layer of the right carotid artery in indicated that the AAV was not specific and 
had infiltrated other tissues (Figure 4.15 4A-D). A limitation of this experiment is that elements 
of the vasculature were causing auto-fluorescence. In a control non AAV-treated carotid artery 
and aortic sinus, there was a small level of red fluorescence in the vascular wall (Figure 4.15 
5A-B). Interestingly, mCherry expression was consistently located to the media and adventitia, 
whereas there was no red fluorescence in any of the foam cell lesions. This could reflect poor 
infiltration of AAV virus but also the mCherry signal may have faded between surgery and 
sectioning of the carotid artery. Loss of fluorescent signals is a problem commonly faced with 
paraffin embedded tissue. In future, it would be useful in addition, to clamp and seal off the 
artery and inject the AAVs into the lumen to promote transduction on the luminal side of the 
vascular wall. Even though the use of mCherry has its limitations, poor transduction of AAV is 
less likely in the current study given the trend in data between groups.  
 
In summary, the results presented in this chapter did not show CaMKIIG2 promoted foam cell 
lesion development. This is likely in part, to reflect low n numbers due to early euthanasia of 
mice post-surgery on welfare grounds. Given the trend in data of CaMKIIG2 compared to 
control groups for foam cell lesion area and stenosis, it is enticing to speculate with a full set 
of animals CaMKIIG2 is likely to promote atherosclerosis. This is the first time the carotid 
ligation approach has been employed in the laboratory and the data suggests that further 
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optimisation of this model is required. Alongside increasing n numbers, this includes sex 
differences, consistency with ligation and improvements with transduction and detection of 
AAV-mCherry. With further optimisation, this model will serve as an excellent tool for 
experiments that use a similar approach. To our knowledge this is the first study to identify 









5.1 Addressing primary aims 
 
The overarching aim of this project was to investigate the role of CaMKII in the early 
development of atherosclerosis. Summarised below are the main findings in the context of 
our initial aims. 
 
 
Aim 1: Identify the major isoforms of CaMKII in human cells of the vasculature and the arteries 
of atherosclerotic mice (ApoE-/-).  
 
Previously we showed that a systemic inhibition of CaMKII by the pharmacological compound 
KN-93 leads to a reduction in foam cell lesion development. A limitation with this study is it 
was a global inhibition of all CaMKII isoforms thus all of the important physiological functions 
that they effect across the different tissues of the body would be impacted. Using RT-PCR, it 
was identified that CaMKIIG1,2,3,6 and CaMKIIJ were the predominant isoforms and the variants 
present in cultured human vascular endothelial cells and smooth muscle cells and the arteries 
of atherosclerotic mice (ApoE-/-). CaMKIIG2 was the predominant form across all samples 
tested inclusive of cells or tissue. Interestingly, Western blotting showed high expression of 
CaMKIIG, but not gamma, in ApoE-/- mice at 13-weeks, before any lesion growth and this 
expression persisted at 20-weeks, where lesions are extensive. Together, this data suggested 
that CaMKIIG was the most likely isoform, and within that isoform, variant 2, to contribute to 
the underlying pathogenesis of atherosclerosis.  
 
 
Aim 2: To knockout the predominant CaMKIIG isoform in ApoE-/- mice and generate the  ApoE-
/-CaMKIIG-/- mouse model to identify the contribution of this specific isoform to foam cell 
lesion development. 
 
As we identified CaMKIIG was the predominant isoform in human vascular cells and the 
arteries of an atherosclerosis model (ApoE-/- mouse), we next employed a genetic approach 
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to further test our hypothesis. ApoE-/- mice were crossed with CaMKIIG-/- mice to generate the 
novel ApoE-/-CaMKIIG-/- (dKO) model. Levels of foam cell lesion content in the aortic sinus of 
female groups was significantly greater than male counterpart groups. A histological 
examination revealed a strikingly significant reduction in foam cell lesion area/ volume in the 
aortic sinus of female ApoE-/-CaMKIIG-/- mice compared to female ApoE-/- (control) mice. 
Collectively, this indicates CaMKIIG signalling promotes foam cell lesion development. 
 
 
Aim 3: To overexpress CaMKIIG2 by AAV transduction, in surgically-ligated carotid arteries of 
ApoE-/- mice to examine the impact of CaMKIIG in foam cell lesion development.   
 
To further test the contribution of CaMKIIG in the early stages of atherosclerosis, an AAV-
mediated over-expression protocol was carried out. At 16-weeks, the left carotid artery of 
ApoE-/-CaMKII-/- mice on a high-fat diet was ligated to increase shear stress and promote the 
development of foam cell lesions. AAV-mCherry particles encoding either the CaMKIIG2 or 
control sequence were introduced to the ligated artery and left to incubate for four weeks. At 
20-weeks carotid arteries of mice displayed a range of foam cell lesions with respect to size 
and morphology. The mean foam cell lesion area was higher in CaMKIIG2-mCherry group 
across the length of the carotid artery however, no significant differences were observed 
when compared to control-mCherry group. This is likely due to low n numbers due to stroke-





There were a number of limitations that need to be discussed and kept in mind when moving 
forward with future experiments. Initially, it was tested what the predominant isoforms of 
CaMKII were in vascular cells. After RT-PCR was used to detect CaMKIIG and J variants, 
Western blotting was used to identify the expression levels. The antibodies used for WB are 
not perfect. In both the G- and J-probed membranes consistently, there was the appearance 
of other bands apart from our target size. This suggests the antibody is not specific but picking 
up proteins that share similar motifs. Therefore, a consistent method for the procedure and 
analysis should be taken to avoid any other variation.  
 
The CaMKIIG knockout model used in Chapter 3 also had its limitations. We were interested in 
the function of CaMKIIG in atherosclerosis, a disease of the arteries, however the model used 
was a global knockdown. We did not measure any other off target effects that are occurring 
in other tissues of the body. This is important as there was evidence in litters bred from the 
dKO colonies to suggest that some mice had adverse effects. These were neurological issues 
such as ataxia as well as developmental problems including malocclusion. These adverse 
effects highlight the need for a more specific approach in future studies.  
 
The carotid artery ligation method was  effective at providing a pro-atherogenic environment 
where we could introduce AAV particles encoding CaMKIIG2 and measure the contribution to 
foam cell lesion growth.  Looking back at the model there are still areas for refinement before 
we utilise this model in the future. Firstly, we need a more consistent ligation approach, to 
avoid high variation in carotid artery foam cell content. Secondly, a more robust introduction 
of the AAV to the carotid artery tissue is required as we only saw AAVs after 4-weeks in the 
tunica media compartment. Also low n-numbers due to unexpected adverse effects meant 
that strong conclusions could not be drawn at times. 
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5.3 Moving forward 
 
No other work to our knowledge has investigated the contribution of CaMKII to the 
development of atherosclerosis. In this thesis, it was identified that CaMKIIG promotes foam 
cell lesion formation (Figure 5.1). This was achieved by using standard molecular biology 
techniques (PCR &WB) and by employing modern genetic approaches and manipulations. Like 




5.3.1 What cell group is the major contributor? 
 
This work has provided foundation evidence that CaMKIIG contributes to atherosclerosis. 
Atherosclerosis is a complicated pathology that involves a number of contributing cell groups 
including ECs, VSMCs and macrophages [13]. The cell groups under investigation in Chapter 2 
were ECs and VSMCs and it was shown CaMKIIG is the predominant isoform. CaMKIIG has roles 
in VSMC proliferation/ migration as well as endothelial dysfunction [212, 218-220, 244]. Both 
of these pathologies are involved in atherosclerosis and this is the likely mechanism by which 
CaMKIIG is having its effect.  
 
Now that it has been identified that CaMKIIG contributes to foam cell lesion development, we 
can now determine what cell group is the biggest contributor. In Chapter 3, knockout of 
CaMKIIG led to a significant reduction in aortic sinus foam cell lesion content. In this model, all 
the splice variants of CaMKIIG and any pathological role they play, were knocked out of all cell 
groups. Compare this with the over-expression experiment in Chapter 4. In this approach, 
CaMKIIG2 was overexpressed in the carotid arteries of ApoE-/-CaMKIIG-/- mice. While the results 
here showed a trend that CaMKIIG promoted carotid foam cell lesion growth, they were not 
significantly different from control. The fact these two experiments showed contrasting 
significance could reflect the fact we have only used one of the eleven identified CaMKIIG 
variants [197, 199, 200, 202]. The variant used in this study, CaMKIIG2, is important in the 
regulation of proliferation and migration in VSMCs [219, 220, 259, 267]. The other well-
documented variant CaMKIIG6 has been more closely associated with endothelial dysfunction 
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[212]. In a future experiment, it would be worth overexpressing other variants in the carotid 
arteries of ApoE-/-CaMKIIG-/- mice including CaMKIIG6 and then both G2 and G6 to get a better 
understanding of the pathological variants and their contribution to atherogenesis. In 
addition, to move forward with the current study, it is critical we identify the impact of 
endothelial specific CaMKIIG signalling plays in comparison with CaMKII activity in VSMCs. This 
can be achieved through the use of Cre-recombinase technology to specifically knockout G 
isoform in endothelial or VSMCs by using a cell specific promoter [268, 269]. 
 
5.3.2 CaMKIIJ  
 
The aim of the current study was to identify the isoform most-likely contributing to early lesion 
development. Our data indicated it was CaMKIIG promoting atherogenesis, however, it was 
not the only isoform present. CaMKIIJ was the other isoform expressed in vascular cells 
(Chapter 2). CaMKIIJ is of particular interest because of the contrasting functions it has shown 
to play in comparison with CaMKIIG. CaMKIIJ has been shown to inhibit VSMC proliferation 
and is important in maintenance of the VSMC contractile phenotype by regulating ion channel 
function and phosphorylating myosin filaments to promote tone [213, 221, 223]. Clearly both 
these isoforms are important in balancing two functional ends of phenotype diversity.  
 
VSMC proliferation is a major mechanism of foam cell lesion development. With CaMKIIJ 
functions in maintenance of the contractile phenotype, it is intriguing to speculate CaMKIIJ 
protects against the development of foam cell lesions. In line with other experiments of 
vascular remodelling CaMKIIJ overexpression by AAV led to a reduction in remodelling and 
promoted contraction [213]. Going forward, it would be worth knocking out CaMKIIJ in the 
ApoE-/- mice and using a similar approach as the methods used for the current thesis, analyse 
foam cell lesion development.   
 
 
5.3.3 Post-translational modifications of CaMKII 
 
The two aspects of studying protein physiology include expression and activity. In the present 
study we were interested in the expression profile of the predominant CaMKII isoforms. It is 
important to keep in mind expression levels do not always directly relate to activity. CaMKII 
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displays a unique mechanism of activation which is tightly regulated. In the inactive state the 
regulatory domain is tightly bound to the catalytic state preventing activity. An elevation in 
intracellular Ca2+ leads to the formation of Ca2+-calmodulin complex, which binds the 
regulatory domain, relieving the auto-inhibitory interaction to carry out kinase function [187]. 
CaMKII remains active until Ca2+ is extruded from the cell (Section 1.5.1). Under conditions of 
prolonged activation CaMKII can undergo inter-subunit auto-phosphorylation of the 
regulatory domain which prevents the auto-inhibitory properties and the enzyme is 
chronically active [188, 189].  
 
In this state of chronic activation, depending on the local environment, CaMKII can also 
undergo additional post-translational modifications including oxidation, nitrosylation and O-
GlyNAcylation [180, 191, 192]. Most of the work on CaMKII in the heart has focused on 
targeting these post-translational modifications to protect against the detrimental cellular 
effects of chronic CaMKII activation [178, 180, 191, 192, 196]. However, in these studies using 
KN-93 as the CaMKII inhibitor remains a limitation as it only blocks the inactive form of CaMKII 
by competing for the calmodulin binding domain to prevent future activation and the addition 
of any post-translational modifications [270]. Hence, any activated CaMKII will remain active 
following KN-93 treatment. A better inhibitor that should be routinely used for CaMKII 
research is autocamtide-2-related inhibitory peptide (AIP). This has benefits over KN-93 as its 
mechanism of action is to block the ATP binding site within the catalytic domain [271]. We 
have previously started to investigate post-translational modifications of CaMKII in 
atherosclerosis. In this study, we have shown that the levels of P-CaMKII do not change from 
early lesion (13-weeks) to mid-lesion (20-weeks) phase (MSc, Worthington, 2016). Increased 
oxidative and nitrosative stress are fundamental elements to the atherosclerotic milieu [272, 
273]. Therefore, in future, it would be useful to identify whether the levels of oxidation and 
nitrosylation of CaMKII contribute to lesion progression. There are already oxidative and 
nitrosative mutants of CaMKII that exist and these can be introduced into the AAV model that 
is now established. 
 
The work carried out in this thesis has been instrumental in establishing this model in the lab, 
and in New Zealand. With further optimisation, the model can be used to establish the role of 
not only other CaMKII variants, but also these mutants that are resistant to post-translational 
modifications. 
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5.3.4 Feasibility of CaMKIIG  as a therapeutic target 
 
This work has made a significant contribution in identifying CaMKII as a therapeutic target for 
treating the early development of atherosclerosis. While these results are promising, it is still 
important to evaluate how this approach would be targeted in the clinic for the treatment of 
human atherosclerosis.  A major difficulty with treating the disease is it is silent for decades 
before any symptoms manifest and importantly, these first symptoms can be life threatening 
[274, 275]. In the current study we identified that CaMKII inhibition protects against 
atherosclerosis during the foam cell lesion phase. This is an early event in the development of 
atherosclerosis and in the clinic atherosclerosis is mainly seen in its advanced stage [95]. It is 
not known how CaMKII inhibition effects atherosclerosis after the foam cell lesion phase. 
Therefore, it is important in the future we investigate how CaMKII promotes lesion growth 
after the foam cell phase and also differentiation of the lesion. Like most diseases, early 
treatment is best and for this treatment better screening and earlier detection of 
atherosclerosis is required so the disease can be treated at an earlier stage. If CaMKII was to 
be a target for early stage atherosclerosis, it would be imperative that the treatment be 
targeted to the coronary arteries because systemically it would target CaMKII in other tissues 




Figure 5.1 Summary of the contribution of PhD work to current CaMKII literature. There are four 
separate genes that encode CaMKII isoforms D, E, G and J. The D and E isoforms are predominantly 
expressed in the nervous system and have important roles in brain function. The G and J isoforms are 
expressed in cardiovascular tissue. Furthermore, the  G isoform has pathological roles in promoting 
endothelial dysfunction and increasing the synthetic phenotype in VSMCs. In contrast the J isoform 
has received little attention, however it has important functions in VSMC contraction. In this PhD we 
have identified CaMKIIG variants 1, 2, 3 and 6 are present in human vascular cells (ECs and VSMCs) as 
well as atherosclerotic arteries of ApoE-/- mice. CaMKIIG promotes lesion development mediated at 
least in part by the G2 variant. The contribution of the other G variants 1, 3 and 6, remains to be 




Atherosclerosis is the most significant cardiovascular disease characterised by the formation 
of fat-filled lesions on the arterial wall. In this novel study, we have utilised a number of 
molecular, genetic and viral-mediated approaches to identify that CaMKIIG promotes 
atherosclerosis. These results provide a strong foundation to continue researching CaMKII 
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